pembrolizumab

Org: Memorial Sloan Kettering Cancer Center, University of Alabama at Birmingham Heersink School of Medicine, University of Kansas Medical Center, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Cleveland Clinic Lerner College of Medicine,

Abstract

Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.

Org: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Michigan, University of Chicago, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA, Division of Hematology and Oncology,

Abstract

SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

Org: Dana-Farber Cancer Institute, University of Chicago Medicine, UNC Lineberger Comprehensive Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Emory University Hospital,

Abstract

Impact of exposure on outcomes with enfortumab vedotin in patients with locally advanced or metastatic urothelial cancer.

Org: Pfizer Inc., Fred Hutchinson Cancer Center, Barts Cancer Institute, University of Colorado Anschutz Medical Campus, Gustave Roussy Cancer Center,

Abstract

International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).

Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,

Abstract

Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.

Org: University of California, San Diego Medical Center, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, Winship Cancer Institute of Emory University,

Abstract

NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.

Org: University College Hospital-London, NHS Foundation Trust, University College London Cancer Institute, The Christie NHS Foundation Trust, University of Leeds,

Abstract

Triplet combination treatments with pembrolizumab (pembro) for anti–PD-(L)1–refractory advanced melanoma: Preliminary results of the phase 1/2 KEYMAKER-U02A study.

Org: University Hospital Zurich, Aix-Marseille University CHU Timone, Hôpital de la Timone, Department of Cancer Medicine, Gustave Roussy Cancer Centre, Gustave Roussy Cancer Campus,

Abstract

A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study.

Org: Department of Medicine, University of Chicago, Johns Hopkins Medicine, University of Pennsylvania, Emory University Winship Cancer Institute, Hollings Cancer Center,

Abstract

A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC).

Org: H. Lee Moffitt Cancer Center and Research Institute, Washington University School of Medicine, University of Washington School of Medicine, Massachusetts General Hospital, Harvard Medical School, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center,

Abstract

Vibostolimab coformulated with pembrolizumab (vibo/pembro) for previously treated advanced mismatch repair–deficient (dMMR) endometrial cancer: Results from cohort B1 of the phase 2 KEYVIBE-005 study.

Org: Bradford Hill Clinical Research Center, Erasmus MC Cancer Institute, Centre Georges-François Leclerc, Dijon, France, Arturo Lopez Perez Foundation Oncology Institute, Institut régional du Cancer de Montpellier (ICM),

Abstract

A phase I/II trial of palbociclib, pembrolizumab, and endocrine therapy for patients with HR+/HER2- locally advanced or metastatic breast cancer (MBC): Clinical outcomes and stool microbial profiling.

Org: City of Hope Comprehensive Cancer Center, Translational Genomics Research Institute (TGen North), Cedars-Sinai Medical Center,

Abstract

TransCon IL-2 β/γ alone or in combination with pembrolizumab, standard of care chemotherapy or TransCon TLR7/8 agonist in advanced/metastatic solid tumors: Updated results of the phase 1/2 IL Believe study.

Org: Gabrail Cancer and Research Center, Cancer Research South Australia,

Abstract

Two phase 2A clinical trials to evaluate the safety and efficacy of IMSA101 in combination with radiotherapy and checkpoint inhibitors in oligometastatic and oligoprogressive solid tumor malignancies.

Org: MetroHealth Cancer Center, University of Wisconsin Madison, Cleveland VA,

Abstract

Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.

Org: University of Pittsburgh Medical Center Hillman Cancer Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Aichi Cancer Center Hospital, Memorial Sloan Kettering Cancer Center, University of Ulsan College of Medicine,

Abstract

Phase 2 trial of brentuximab vedotin (BV) with pembrolizumab (pembro) in patients with previously treated metastatic non-small cell lung cancer (NSCLC) or cutaneous melanoma (SGN35-033): Overall survival.

Org: Blue Ridge Cancer Care, Oncology Hematology Care, Inc.,

Abstract

Investigation of a potential protein biomarker signature that may predict clinical benefit of NT-I7 and pembrolizumab in patients with cold gastrointestinal tumors.

Org: GENINUS Inc.,

Abstract

A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability.

Org: Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Illumina Inc., Fortrea Inc.,

Abstract

Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.

Org: Memorial Sloan Kettering Cancer Center, University of Bari "A. Moro" and Policlinico Consorziale, Kyushu University, Texas Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea,

Abstract

Neoadjuvant/adjuvant pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for gastric/gastroesophageal junction (G/GEJ) adenocarcinoma: Major pathologic response (mPR) in KEYNOTE-585.

Org: Chonnam National University Medical School, Hwasun, South Korea, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy, Universidad de La Frontera, James Lind Cancer Research Center, Temuco, Chile, National Cheng Kung University, Tainan, Taiwan, CHU Brest–Institut de Cancerologie et d’Hematologie ARPEGO Network, Brest, France,

Abstract

Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.

Org: Winship Cancer Institute at Emory University,

Abstract

Org: UTEC Hospital Clínico San Carlos, START Madrid - CIOCC, Waltham,

Abstract

SU2C-SARC032: A randomized trial of neoadjuvant RT and surgery with or without pembrolizumab for soft tissue sarcoma.

Org: UPMC Hillman Cancer Center, Mayo Clinic Rochester, Melanoma Institute Australia, University of Sydney and Sydney Cancer Centre, Chris O'Brien Lifehouse,

Abstract

Efficacy, safety, and PK/PD of LVGN6051, 4-1BB agonistic antibody, with pembrolizumab in a phase Ib dose expansion in resistant NSCLC, melanoma, and GI malignancy.

Org: UCI Health, Horizon Oncology & Research Center,

Abstract

A pilot study of early PET and biomarker dynamics in patients with stage 2 and 3 triple negative breast cancer treated with neoadjuvant response-adapted chemotherapy with pembrolizumab (NeoADAPT).

Org: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Department of Radiology at Johns Hopkins,

Abstract

Incidence and time to onset of immunotherapy-related adrenal insufficiency in the I-SPY2 trial.

Org: University of Chicago Medicine, University of Chicago, University of California, San Francisco Department of Medicine, University of California, San Francisco Department of Surgery, University of California, San Francisco,

Abstract

Real-world immune-related adverse events in patients with early triple negative breast cancer who received pembrolizumab.

Org: Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Wesleyan University, Department of Breast Medical Oncology, Division of Cancer Medicine,

Abstract

A randomized phase 2 trial of the IO102-IO103 (IDO and PD-L1) cancer vaccine plus pembrolizumab as neoadjuvant/adjuvant treatment of patients with solid tumors.

Org: Institute Gustave Roussy and Paris Saclay University, Dermatology Department Hospital Center University De Lille, Department of Dermatology Comprehensive Cancer Center, Westdeutsches Tumorzentrum University Hospital Essen & Research Alliance Ruhr & Research Center One Health University Duisburg-Essen, Department of Medical Oncology Dana-Farber Cancer Institute,

Abstract

Phase 1/2 trial of the HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab: Clinical update.

Org: Frauenshuh Cancer Center, Nimbus Therapeutics, Florida Cancer Affiliates, Honor Health Research Institute,

Abstract

A phase 1b study of NC410 in combination with pembrolizumab in immune checkpoint inhibitor (ICI) naïve, and refractory microsatellite stable (MSS)/microsatellite instability-low (MSI-L) colorectal cancer (CRC) and ovarian cancer.

Org: Merck and Co Inc, NextCure Inc,

Abstract

Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Massachusetts General Hospital, Department of Radiation Oncology, UCLA Health Jonsson Comprehensive Cancer Center, Los Angeles, CA,

Abstract

Org: Shanghai Pulmonary Hospital, Shanghai, China, AOU San Luigi, University of Torino, Hospital Ramón y Cajal, University Hospitals KU Leuven,

Abstract

NeoTRACT: Phase II trial of neoadjuvant tumor infiltrating lymphocyte- and response-adapted chemoimmunotherapy for triple-negative breast cancer (TNBC).

Org: University of Kansas Medical Center, ZAS Hospitals, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, University of Kansas Cancer Center,

Abstract

Phase 1/2 study of NGM707, an ILT2/ILT4 dual antagonist antibody, in advanced solid tumors: Interim results from dose-escalation.

Org: China Medical University Hospital, NGM Biopharmaceuticals, Inc.,

Abstract

Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.

Org: LMU University Hospital Munich, Interdisciplinary Breast Center, Rotkreuz-Clinics Munich, West German Study Group, Ev. Hospital Bethesda,

Abstract

Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.

Org: Department of Hematology, Oncology and Radiation Physics, Skane University Hospital Comprehensive Cancer Center, Lund, Sweden, Karolinska Comprehensive Cancer Center, Stockholm, Sweden, OU Health Stephenson Cancer Center, Oklahoma City, OK, Sahlgrenska University Hospital, Gothenburg, Sweden, Health Partners, Saint Paul, MN,

Abstract

Phase 1 trial of TU2218, TGFβ-RI and VEGF-R2 dual inhibitor in monotherapy and combination with pembrolizumab in patients with advanced solid tumors.

Org: Medical Oncology Associates, Hope Cancer Center of East Texas,

Abstract

Pertuzumab plus trastuzumab (P+T) in patients (pts) with solid tumors with ERBB2 or ERBB3 amplification (amp) or mutations (mut): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

Org: Michigan Cancer Research Consortium, City of Hope - Chicago, Division of Hematology and Oncology, Department of Medicine, O’Neal Comprehensive Cancer Center of University of Alabama at Birmingham, Heersink School of Medicine, Intermountain Healthcare, Cancer Research Consortium of West Michigan,

Abstract

Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.

Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,

Abstract

Multiomic factor analysis for pathologic complete response (pCR) after 12 weeks of pembrolizumab + trastuzumab + pertuzumab in HER2-enriched (HER2-E) early breast cancer (eBC) in the Keyriched-1 trial.

Org: West German Study Group, Moenchengladbach, Germany, Queen Mary University of London, London, United Kingdom, Medical School Brandenburg, Institute for Biometrics and Registry Research, Neuruppin, Neuruppin, Germany,

Abstract

Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.

Org: Medical University of Gdańsk, Gdańsk, Poland, International Centre for Thoracic Cancers (CICT), Gustave Roussy Cancer Center, Department of Oncology, Asan Medical Centre, University of Ulsan College of Medicine,

Abstract

Trends in prices of checkpoint inhibitors in the US, 2016-2023.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

Cln-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab (P) for advanced solid tumors: Updated results of a Ph1 study.

Org: University of Western Australia & Linear Clinical Research, Monash Medical Centre, Biokinetic, Parc Taulí Institute of Research and Innovation I3PT, Maria Sklodowska Curie National Research Institute of Oncology,

Abstract

Efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, and pembrolizumab in patients with immune checkpoint inhibitor-naive unresectable or metastatic melanoma: Updated results from IOV-COM-202 cohort 1A.

Org: Orlando Health Cancer Institute, First Department of Medicine, National and Kapodistrian University of Athens, Cooper University Hospital, Norris Comprehensive Cancer Center,

Abstract

A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).

Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY,

Abstract

Circulating immune protein biomarkers of early response and resistance in patients with metastatic HER-2–negative esophagogastric cancer (mEGC) treated with pembrolizumab and chemotherapy.

Org: Olink Proteomics AB,

Abstract

Safety and efficacy of first-in-class CXCR1/2 inhibitor SX-682 in combination with pembrolizumab (pem) in patients (pts) with metastatic melanoma (mMEL) with disease progression on anti–PD-1 therapy.

Org: Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Mayo Clinic, Rochester, MN, USA, University of Rochester, Rochester, NY, Massachusetts General Hospital, Marblehead, MA, Dana-Farber Cancer Institute, Boston, MA, USA,

Abstract

Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM).

Org: The Angeles Clinic and Research Institute, a Cedars-Sinai Affiliate, Los Angeles, CA, HCA Healthcare global Sarah Cannon Research Institute, London, United Kingdom, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, University of Chicago, Comprehensive Cancer Center, Chicago, IL, Jefferson Medical College, Philadelphia, PA,

Abstract

Final analysis of 2-THE-TOP: A phase 2 study of TTFields (Optune) plus pembrolizumab plus maintenance temozolomide (TMZ) in patients with newly diagnosed glioblastoma.

Org: Department of Neurological Surgery, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, University of Florida Department of Neurosurgery, University of Southern California Department of Neurological Surgery,

Abstract

Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.

Org: University Hospital Marqués de Valdecilla, IDIVAL, Santander, Spain, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil, Pontifica Catholic University of Chile, Santiago, Chile, IMAT-Oncomedica, Monteria, Colombia, Trinity St. James Cancer Institute, Dublin, Ireland,

Abstract

Ultra-sensitive ctDNA dynamics to capture therapy response in pembrolizumab-treated gastroesophageal cancer.

Org: Duke University Medical Center, Durham, NC, Personalis, Inc., Menlo Park, CA, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

A phase 2a safety run-in and preliminary efficacy study of liposomal gemcitabine (FF-10832) in combination with pembrolizumab in patients with advanced solid tumors.

Org: Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ, FUJIFILM Pharmaceuticals USA, FUJIFILM Corporation,

Abstract

Acasunlimab (DuoBody-PD-L1x4-1BB) alone or in combination with pembrolizumab (pembro) in patients (pts) with previously treated metastatic non-small cell lung cancer (mNSCLC): Initial results of a randomized, open-label, phase 2 trial.

Org: Department of Pulmonary Diseases, Erasmus MC, Rotterdam, Netherlands, Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain, Clinical Research Unit, Military Hospital Begin, Saint-Mandé, France, Hopital Morvan CHU de Brest, Brest, France, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland,

Abstract

Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.

Org: Hematology Oncology Association of the Treasure Coast,

Abstract

19-BI-1808-01, a phase 1/2a clinical trial of BI-1808, a tumor necrosis factor receptor 2 (TNFR2) blocker/depleter with or without pembrolizumab.

Org: MH Egeszsegugyi Kozpont, Budapest, Hungary, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, PRA Health Sciences, Budapest, Hungary, University of Southampton, Southampton, United Kingdom,

Abstract

Multi-ethnic genome-wide association study to identify a novel locus for susceptibility to immune-related adverse events from immune checkpoint inhibitors.

Org: Department of Haematology Oncology, National University Cancer Institute Singapore, Department of Haematology-Oncology, Rheumatology Division, National University Hospital,

Abstract

A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors.

Org: Division of Hematology/Oncology, University of Cincinnati Cancer Center,

Abstract

Tregs, gMDSCs, and levels of soluble MICA as prognostic biomarkers for combined NEO-201 and pembrolizumab.

Org: Women’s Malignancies Branch, Precision Biologics, Inc., Thoracic and Gastrointestinal Malignancies Branch,

Abstract

A phase 1/1b first-in-human (FIH) study of JZP898 as monotherapy and in combination with pembrolizumab in adult patients with advanced or metastatic solid tumors.

Org: Sarah Cannon Research Institute/Tennessee Oncology, Baylor University Medical Center, Texas Oncology, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Cancer Center at Thomas Jefferson University,

Abstract

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody (mAb) MK-0482 + pembrolizumab (pembro) in patients with recurrent inoperable glioblastoma (GBM).

Org: Seoul National University Hospital, Asan Medical Center, University of Ulsan College of Medicine, John Theurer Cancer Center at Hackensack Meridian Health, Hackensack University Medical Center,

Abstract

Pembrolizumab (pembro) in patients (pts) with sorafenib-treated (cohort 1) and treatment (tx)-naive (cohort 2) advanced hepatocellular carcinoma (aHCC) after additional follow-up in the phase 2 KEYNOTE-224 study.

Org: Saint-Luc University Clinics, Brussels, Belgium, Eugène Marquis Center, Rennes, France, Claude Huriez Hospitals, Lille University Hospital, Lille, France, Ghent University Hospital, Ghent, Belgium, CR UK Liverpool Experimental Cancer Medicine Centre and Clatterbridge Cancer Centre, Liverpool, United Kingdom,

Abstract

A phase 2a study of NT-I7 (efineptakin alfa), a long-acting IL-7, and pembrolizumab to evaluate efficacy, including overall survival, in hard-to-treat gastrointestinal tumors.

Org: H. Lee Moffitt Cancer Center and Research Institute, Barbara Ann Karmanos Cancer Institute, Mary Crowley Cancer Research, Sarah Cannon Research Institute/Tennessee Oncology, NeoImmuneTech, Inc.,

Abstract

Results from phase 1a/1b analyses of TTX-080, a first in class HLA-G antagonist, in combination with cetuximab in patients (pts) with metastatic colorectal cancer and head and neck squamous cell carcinoma.

Org: University of Okahoma Health Sciences Center,

Abstract

Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.

Org: University Croix-Rousse Hospital, University Hospital of Lyon, Lyon, France, Istinye University, Istanbul, Turkey, Purpan Hospital, Toulouse, France, Chinese University of Hong Kong, Hong Kong, China, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada,

Abstract

A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumab.

Org: Earle A Chiles Research Institute, Werewolf Therapeutics Inc, Cogitars GmbH,

Abstract

A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1).

Org: Division of Thoracic Surgery,

Abstract

Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).

Org: University of Colorado Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Colorado Anschutz Medical Campus, Inova Schar Cancer Institute,

Abstract

A multi-centre, single arm, phase 2 trial of pembrolizumab in treatment-naïve patients with carcinoma of unknown primary site.

Org: Edmonton, AB, Canada, University of Ottawa, The Ottawa Hospital Regional Cancer Centre,

Abstract

Phase I/II trial of LAVA-1207, a novel bispecific gamma-delta T-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC).

Org: Department of Medical Oncology, Amsterdam UMC, START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Medical Oncology Department, Catalan Institute of Cancer (ICO), Cancer Immunotherapy Group (CIT), Bellvitge Biomedical Research Institute (IDIBELL) —OncoBell, Early Phase Drug Development Program START Madrid-CIOCC, Centro Integral Oncológico Clara Campal,

Abstract

Impact of hepatitis B virus (HBV) infection on efficacy and safety in the KEYNOTE-966 study of pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) for advanced biliary tract cancer (BTC).

Org: Amsterdam UMC, University of Amsterdam, ENETS Center of Excellence, Cancer Center Amsterdam, Charite Campus Charite Mitte,

Abstract

A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.

Org: NextGen Oncology,

Abstract

PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.

Org: Department of Interventional Radiology,

Abstract

Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC).

Org: Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Department of Gastroenterology, Hepatobiliary and Pancreatic Medical Oncology Division, Kanagawa Cancer Center, Prince of Wales Hospital, Department of Clinical Oncology, The Chinese University of Hong Kong, Amsterdam UMC, University of Amsterdam, Department of Medical Oncology, ENETS Center of Excellence, Cancer Center Amsterdam, Gastroenterology, Hepatology, Infectious Diseases and Endocrinology Department, Hannover Medical School,

Abstract

Perioperative pembrolizumab and lenvatinib for resectable hepatocellular carcinoma: A single-arm, multi-center, phase II trial (NeoLEAP-HCC).

Org: Liver Cancer Institute, Department of Hepatic Surgery II, Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), Department of Hepatic Surgery V, Center of Hepato-Pancreato-Biliary Surgery,

Abstract

Therapeutic implications of acquired high tumor mutational burden (TMB-H) after targeted therapy (TT) in metastatic colorectal cancer (mCRC).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.

Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,

Abstract

Informing optimal treatment (tx) sequences for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma (la/mUC) in the United States: Results of a clinical simulation modeling exercise.

Org: Evidera, Inc, EMD Serono Research & Development Institute, The Healthcare Business of Merck KGaA,

Abstract

FGFR3 alterations (FGFRalt) in patients (pts) who develop locally advanced or metastatic urothelial cancer (mUC), and their association with tumor subtype and clinical outcomes in pts treated with erdafitinib (erda) vs. pembrolizumab (pembro).

Org: Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Greenberg Bladder Cancer Institute,

Abstract

Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).

Org: IRCCS San Raffaele Hospital and Scientific Institute, Division of Hematology/Oncology, UCLA David Geffen School of Medicine,

Abstract

PROTA: A phase I clinical trial combining an oncolytic adenovirus encoding for TNFa and IL-2 with pembrolizumab for the treatment of platinum-resistant or -refractory ovarian cancer.

Org: TILT Biotherapeutics, Mayo Clinic, Docrates Cancer Center, Cancer Gene Therapy Group, Merck & Co., Inc.,

Abstract

A phase 1/2 study of favezelimab in combination with pembrolizumab for anti–PD-1–naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An updated analysis.

Org: School of Clinical Sciences at Monash Health, Concord Hospital,

Abstract

Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College,

Abstract

TRITON: Phase 3b study of tremelimumab (T) + durvalumab (D) vs pembrolizumab (P), in combination with chemotherapy (CT), in non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11 and/or KEAP1 and/or KRAS mutations.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Fox Chase Cancer Center, David Geffen School of Medicine at UCLA, Winship Cancer Institute at Emory University, Georgetown University Medical School,

Abstract

Cadonilimab plus lenvatinib in patients with advanced endometrial cancer: A multicenter, single-arm, phase II trial.

Org: The Third Affiliated Hospital Kunming Medical University,

Abstract

Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

Org: Ramat Gan, Hadassah Hebrew - University Medical Center, Jerusalem, Medical Oncology and Immunotherapy, Siena,

Abstract

Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.

Org: John Wayne Cancer Institute, Centre hospitalier de l’Université de Montréal (CHUM), Centre de recherche du CHUM, Skåne University Hospital Comprehensive Cancer Centrer and Lund University, Hospital General Universitario Gregorio Marañón and CIBERONC,

Abstract

First-line pembrolizumab for lung cancer in a Spanish real-world study.

Org: Hospital Universitario Dr. Balmis de Alicante ISABIAL, Hospital Universitario La Coruña, Oncology Pharmacy Department, Catalan Institute of Oncology-Hospitalet, Hospital Universitario de Asturias,

Abstract

STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma.

Org: Winship Cancer Institute, Emory University, Atlanta, GA, USA, The Institute of Cancer Research/The Royal Marsden Hospital, Fondazione IRCCS Istituto Nazionale Tumori and University of Milan, Cliniques Universitaires Saint-Luc,

Abstract

Belzutifan plus lenvatinib (len) for Chinese patients (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Preliminary results of cohort 1 of the phase 1 LITESPARK-010 study.

Org: The Affiliated Hospital of Nanjing University Medical School, MSD (China) Co., Ltd.,

Abstract

Outcomes of patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer who demonstrated nonresponse to pembrolizumab in KEYNOTE-057: A post hoc analysis.

Org: MSD Netherlands,

Abstract

A phase 2 study of ipatasertib in combination with pembrolizumab for first-line treatment of recurrent or metastatic squamous cell cancer of the head and neck.

Org: City of Hope Antelope Valley, Lancaster, CA, San Diego, La Jolla, CA,

Abstract

The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non–small-cell lung cancer (NSCLC).

Org: Moderna, Inc., Merck & Co., Inc.,

Abstract

REPLACE: A phase III, randomized, open-label trial to evaluate the safety and efficacy of regorafenib and pembrolizumab versus locoregional therapy (LRT) with transarterial chemoembolization (TACE) or transarterial radioembolization (TARE), for the first-line treatment of intermediate-stage hepatocellular carcinoma (HCC) with beyond up-to-7 criteria.

Org: IDIBAPS, Hospital Clinic Barcelona, University of Barcelona, Barcelona, Spain, Institució Catalana d’Estudis Avançats (ICREA), Barcelona, Spain, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, Translatoinal Research in Oncology (TRIO), Montevideo, Uruguay, Translational Research in Oncology (TRIO), Edmonton, AB, Canada,

Abstract

A phase III randomized trial of eribulin (E) with gemcitabine (G) vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937 updated design.

Org: Davis Comprehensive Cancer Center, Swog Gu Bladder Patient Advocate,

Abstract

A phase 2 trial of IO102-IO103 and nivolumab-relatlimab fixed-dose combination in previously untreated, unresectable melanoma.

Org: Lehigh Valley Topper Cancer Institute,

Abstract

Overestimation of survival in individuals with cancer treated in the real world with new cancer drugs: A population-based cohort study.

Org: BC Cancer-Vancouver Centre, University of British Columbia,

Abstract

Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer.

Org: Clinical Oncology School of Fujian Medical University,

Abstract

Outcomes of reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.

Org: Kaiser Permanente San Diego, Kaiser Permanente National Drug Use Management,

Abstract

Enfortumab vedotin plus pembrolizumab in the treatment of locally advanced or metastatic bladder cancer of variant histology: A phase II study.

Org: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Department of Pathology, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University, Atlanta, GA,

Abstract

FDA analysis of immune checkpoint inhibitors in combination with vascular endothelial growth factor tyrosine kinase inhibitors in the second-line treatment of patients with advanced non-small cell lung cancer.

Org: U.S. Food and Drug Administration, Silver Spring, MD, Office of Oncologic Diseases, Center for Drug Evaluation and Research, Oncology Center of Excellence,

Abstract

Phase 2 study of pembrolizumab plus pemetrexed for older patients with non-squamous non-small cell lung cancer with PD-L1 tumor proportion score of less than 50%: CJLSG1901.

Org: Osaka City General Hospital, Japanese Red Cross Okayama Hospital, Tosei General Hospital, Toyohashi Municipal Hospital, Matsunami General Hospital,

Abstract

The preliminary efficacy and safety results of neoadjuvant phase 2 study of penpulimab combined with taxanes and carboplatin in triple-negative breast cancer (neoTAPPL).

Org: Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Key Laboratory of Minimally Invasive Surgery and Precision Treatment for Breast Cancer of Chongqing Municipal Health Commission, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Sounthwest Hospital, Army Medical University, Chongqing, China, Department of Breast and Thyroid Surgery, Southwest Hospital, Army Medical University; Department of Thoracic Surgery, the Eighth Medical Center of Chinese PLA General Hospital, Chongqing, China, Central Medical Center, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. L., Nanjing, China,

Abstract

EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.

Org: Beijing TongRen Hospital, Internet Hospital of Tianjin Medical University General Hospital, Tianjin First Central Hospital,

Abstract

Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.

Org: Winship Cancer Institute of Emory University, Atlanta, GA, University of Alabama at Birmingham, Birmingham, AL, University of California, San Francisco, San Francisco, CA, University of California, San Diego, La Jolla, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA,

Abstract

Updated interim analysis of a phase I/Ib study of enfortumab vedotin plus cabozantinib in patients with metastatic urothelial carcinoma.

Org: Winship Cancer Institute of Emory University, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA,

Abstract

Cost-effectiveness in perioperative therapy in the era of immune checkpoint inhibitors.

Org: Juntendo University Graduate School of Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine,

Abstract

Cardiotoxicity of immune checkpoint inhibitors: A retrospective cohort study of 93,362 patients.

Org: Baylor University Medical Center, Dallas, TX,

Abstract

A phase 2/3 study of Bicycle toxin conjugate BT8009 targeting nectin-4 in patients with locally advanced or metastatic urothelial cancer (la/mUC): Duravelo-2.

Org: University Paris Saclay,

Abstract

Phase II study of pembrolizumab and lenvatinib in platinum sensitive recurrent ovarian cancer.

Org: Department of Physiology and Pharmacology, Faculty of Medicine, Tel-Aviv University, Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University,

Abstract

Different dosing strategies of pembrolizumab in the treatment of NSCLC: A real-world retrospective observational study.

Org: University Clinic Golnik, University of Ljubljana, Faculty of Pharmacy,

Abstract

PD-1 checkpoint inhibitors related immune-mediated hepatitis in colon cancer: A systematic review and meta-analysis.

Org: New York Medical College - Saint Michael's Medical Center, Landmark Medical Center,

Abstract

Clinical outcomes of sacituzumab govitecan (SG) after prior exposure to enfortumab vedotin (EV) in patients with metastatic urothelial carcinoma (mUC).

Org: Memorial Sloan Kettering Cancer Center, Barts Cancer Institute, Queen Mary University of London, Genitourinary Oncology Service, Weill Cornell Medical College University,

Abstract

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients with muscle invasive bladder cancer (MIBC)—2-year event-free survival and safety data for Cohort H.

Org: University Hospitals Case Medical Center, Piedmont Cancer Institute, P.C.,

Abstract

Early signs of efficacy in patients with anti-PD-1 naïve and anti-PD-1 resistant HNSCC treated with NBTXR3/SBRT in combination with nivolumab or pembrolizumab in the phase I trial Study 1100.

Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Johns Hopkins Medicine, University of Chicago, Nanobiotix,

Abstract

First-line systemic therapy following adjuvant immunotherapy in renal cell carcinoma (RCC): An international multi-center study.

Org: Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, Dana-Farber Cancer Institute, Boston, MA, Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, Rogel Comprehensive Cancer Center, Ann Arbor, MI, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada, Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic, City of Hope Comprehensive Cancer Center, Duarte, CA, Genitourinary Medical Oncology, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, Campus Biomedico, Roma, Italy, University Hospital of Parma, Fontevivo, Italy, Beatson West of Scotland Cancer Centre, University of Glasgow, Glasgow, United Kingdom, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, Vanderbilt University Medical Center, Nashville, TN, Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada, The Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, MA,

Abstract

Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC): Subgroup analysis from TROPION-Lung02.

Org: CNIO-H12O Lung Cancer Unit, Departamento de Investigacion de Cancer de Pulmon, Hospital Universitario 12 de Octubre, CNIO-H12O Lung Cancer Unit, Department of Oncology, National Cheng Kung University Hospital, Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Università degli Studi di Milano-Bicocca,

Abstract

Sacituzumab govitecan (SG) plus enfortumab vedotin (EV) for metastatic urothelial carcinoma (mUC) treatment-experienced (DAD) and with pembrolizumab (P) in treatment naïve UC (DAD-IO).

Org: Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, AdventHealth Cancer Institute, The Lank Center for Genitourinary Oncology,

Abstract

Pathologic response rates to neoadjuvant pembrolizumab in locally advanced (LA) resectable cutaneous squamous cell carcinoma (cSCC).

Org: UPMC Health System, Predxbio,

Abstract

Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.

Org: New Experimental Therapeutics (NEXT), START San Antonio, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Merck & Co., Inc.,

Abstract

A phase II multicenter study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors (E-VIRTUE).

Org: Genitourinary Malignancies Branch, CCR, NCI, NIH, Bethesda, MD, Laboratory of Pathology, CCR, NCI, NIH, Bethesda, MD, Urologic Oncology Branch, CCR, NCI, NIH, Bethesda, MD, Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, Biostatistics and Data Management Section, OCD, NCI, NIH, Bethesda, MD,

Abstract

Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A prospective, single-arm, open-label, phase 2 study.

Org: National Clinical Research Centre for Cancer,

Abstract

Association of RNA-sequencing signatures with clinical outcomes of pembrolizumab + chemotherapy in patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) enrolled in the phase 2 KEYNOTE-782 trial.

Org: Complutense University and CIBERONC, Tel-Aviv University Medical School, Central University Hospital of Asturias, Insular Maternal-Child University Hospital Complex of Gran Canaria, University of Las Palmas de Gran Canaria,

Abstract

eVOLVE-HNSCC: A global phase 3 study of volrustomig as sequential therapy for unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) following definitive concurrent chemoradiotherapy (cCRT).

Org: Head and Neck Medical Oncology Unit, Department of Oncology and Hemato-Oncology University of Milan,

Abstract

Neoadjuvant hypofractionated radiotherapy combined with pembrolizumab plus chemotherapy for potentially resectable non-small cell lung cancer: A phase Ib study.

Org: Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, China Jinagsu Province Institute of Cancer Research,

Abstract

Safety of tabelecleucel with pembrolizumab in recurrent/metastatic Epstein–Barr virus-associated nasopharyngeal carcinoma.

Org: Stanford Cancer Center, University of Pennsylvania, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, City of Hope Comprehensive Cancer Center Department of Medical Oncology and Therapeutics Research,

Abstract

A pilot study of tazemetostat and pembrolizumab in advanced urothelial carcinoma (ETCTN 10183).

Org: Cancer Therapy Evaluation Program - National Cancer Institute,

Abstract

Efficacy of pembrolizumab monotherapy and in combination with BCR inhibitors for Richter transformation of chronic lymphocytic leukemia (CLL).

Org: Mayo Clinic, Stanford University Medical Center, Stanford, CA,

Abstract

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD-1 therapy in patients with metastatic melanoma.

Org: IEO European Institute of Oncology IRCCS, Merck and Co Inc Kenilworth,

Abstract

EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating γ9δ2 T cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma.

Org: Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Sutton, United Kingdom, Center for Cancer Immunotherapy, Nice, France, Oullins-Pierre-Bénite, France,

Abstract

Expert consensus recommendations on the daily clinical use of pembrolizumab for early triple-negative breast cancer.

Org: Chinese University of Hong Kong Medical Centre, Department of Medicine, The University of Hong Kong, United Christian Hospital, Hong Kong Baptist Hospital, Kwong Wah Hospital,

Abstract

Recent safety and efficacy findings from a phase 1b/2 open-label combination study of ASP-1929 photoimmunotherapy with anti-PD-1 therapy in EGFR-expressing advanced head and neck squamous cell carcinoma (HNSCC).

Org: Thomas Jefferson University, University of Miami Miller School of Medicine, Miami, FL, University of Kentucky, Lexington, KY, Rakuten Medical, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE study: JCOG1701).

Org: Department of Medical Oncology, Kyorin University Faculty of Medicine, Mitaka, Japan, JCOG Data Center/Operations Office, National Cancer Center, Tokyo, Japan, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan, Miyagi Cancer Center, Natori-Shi, Japan,

Abstract

Novel RNA-nanoparticle vaccine for the treatment of early melanoma recurrence following adjuvant anti-PD-1 antibody therapy.

Org: University of Florida Department of Surgery, University of Florida College of Public Health and Health Professions, University of Florida Brain Tumor Immunotherapy Program, Preston A. Wells, Jr. Center for Brain Tumor Therapy,

Abstract

A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer.

Org: Cancer Vaccine Institute, UW Medicine, Precigen, Inc.,

Abstract

NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.

Org: Division of Oncology/Unit of Urology, Urological Research Institute, Urology Unit,

Abstract

Neoadjuvant combination treatment of olaparib and pembrolizumab for patients with HRD-positive advanced ovarian cancer.

Org: Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan, Department of Gynecology, NHO Shikoku Cancer Center, Matsuyama, Japan, Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan, Department of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer.

Org: Translational Tumor Immunology Program, NIDCD, OCD, Center for Clinical Research,

Abstract

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP-OLIGO study (WJOG11118L): Feasibility analysis of induction therapy and local ablative therapy.

Org: Radiation and Proton Therapy Center, Shizuoka Cancer Center, Division of Thoracic Surgery, Shizuoka Cancer Center, Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Department of Clinical Radiology, Graduate School of Medical Sciences, Department of Radiation Oncology, Juntendo University, Graduate School of Medicine,

Abstract

Outcomes of advanced/metastatic breast cancer (aMBC) treated with BRIA-IMT, an allogeneic whole cell immunotherapy.

Org: Tranquil Clinical Research,

Abstract

A phase II trial of sitravatinib plus nivolumab after progression on prior immune checkpoint inhibitor (ICI) in patients with metastatic clear cell renal cell carcinoma (ccRCC).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Indiana University Simon Comprehensive Cancer Center, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, University of Chicago, Chicago, IL, Department of Medicine, Division of Hematology and Oncology, The Medical College of Wisconsin, Milwaukee, WI, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, Mary Crowley Cancer Research, Dallas, TX, AdventHealth Cancer Institute, Orlando, FL, Sarah Cannon Research Institute, Nashville, TN, St. Jude Crosson Cancer Institute/Providence Medical Foundation, Fullerton, CA, Fort Wayne Medical Oncology - West Jefferson Office, Fort Wayne, IN, Scholar Rock Inc., Cambridge, MA, Scholar Rock, Cambridge, MA, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,

Abstract

A phase 1/2 study of favezelimab in combination with pembrolizumab for heavily pretreated anti–PD-1–refractory classical Hodgkin lymphoma (cHL): An updated analysis.

Org: Merck & Co., Inc., City of Hope National Medical Center,

Abstract

A phase 1/2 study of the TBL1 inhibitor, tegavivint (BC2059), in patients (pts) with advanced hepatocellular carcinoma (aHCC) with β-catenin activating mutations.

Org: University of Texas Southwestern Medical School, The University of Chicago Medicine Comprehensive Cancer Center, The University of Edinburgh, Cancer Research UK Beatson Institute, CR-UK Beatson Institute & MRC Centre for Inflammation Research,

Abstract

Effect of antibiotic, proton pump inhibitor, H2 blocker, metformin and statin use on outcomes with immune checkpoint inhibitors (ICIs) in patients (pts) with metastatic urothelial carcinoma (mUC) in a real-world setting.

Org: John D. Dingell VA Hospital,

Abstract

Sacituzumab govitecan (SG) + pembrolizumab (pembro) in first-line (1L) metastatic non-small cell lung cancer (mNSCLC) with PD-L1 ≥ 50%: Cohort A of EVOKE-02.

Org: Northwestern University Feinberg School of Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Regional and Virgen de la Victoria University Hospitals, IBIMA, Hospital Clínic de Barcelona, IDIBAPS,

Abstract

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings.

Org: Department of Biostatistics, Bioinformatics and Biomathematics, Georgetown University,

Abstract

Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).

Org: Department of Obstetrics and Gynaecology, Pokfulam, Yaumatei, Pamela Youde Nethersole Eastern Hospital, Chai Wan,

Abstract

Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202).

Org: The Royal Marsden Hospital and The Institute of Cancer Research,

Abstract

A phase 2 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab and chemotherapy in patients with stage 4 non-small cell lung cancer.

Org: White Plains Hospital, Center for Cancer Care, White Plains, NY, Medstar Franklin Square Medical Center,

Abstract

Evaluation of the genomic and immune profiles of patients with lung adenosquamous carcinoma (LUAS) and association of response to treatment.

Org: Caris Life Sciences, Irving, TX, The Warren Alpert Medical School of Brown University, Columbia University Irving Medical Center, New York, NY, USA, Yale Cancer Center, Penn State Milton S. Hershey Medical Center, Hershey, PA,

Abstract

Tazemetostat in combination with topotecan and pembrolizumab in patients with recurrent small cell lung cancer.

Org: Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Philadelphia, PA, National Cancer Center Hospital East, Kashiwa, Japan, Shinjuku-Ku, Japan,

Abstract

INSIGHT-005: A new stratum of the explorative, open-labeled, phase I INSIGHT study to evaluate the feasibility and safety, as well as preliminary efficacy, of subcutaneous injections with IMP321 (eftilagimod alpha) in combination with PD-L1 inhibitor (avelumab) for metastatic or unresectable locally advanced urothelial carcinoma (UC)—IKF-s614.

Org: Universitätsklinik Tübingen, Klinik für Urologie, University Medical Center of the Johannes Gutenberg-University Mainz, Hematology Oncology Practice Eppendorf (HOPE), University Cancer Center Hamburg (UCCH),

Abstract

Enfortumab vedotin and pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: A cohort of the EV-202 trial.

Org: University of Michigan Rogel Cancer Center, University of Chicago, Dana-Farber Cancer Institute, University of Wisconsin, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

eVOLVE-Lung02: A phase 3 study of first-line (1L) volrustomig plus chemotherapy (CT) versus pembrolizumab plus CT in metastatic non-small-cell lung cancer (mNSCLC) with PD-L1 tumor cell (TC) expression <50%.

Org: Hospital del Mar-CIBERONC, Institute Curie,

Abstract

Final results of CORE-001: A phase-2, single arm study of cretostimogene grenadenorepvec in combination with pembrolizumab in patients with BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ.

Org: Division of Urology, Perelman School of Medicine at the University of Pennsylvania, BCG Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chesapeake Urology, Spokane Urology,

Abstract

Safety and immunological effects of ablative radiotherapy followed by pembrolizumab in patients with advanced adrenocortical carcinoma.

Org: Memorial Sloan Kettering Cancer Center, New York, NY, Department of Epidemiology & Biostatistics,

Abstract

SUNRAY-01, a pivotal, global study of olomorasib (LY3537982) in combination with pembrolizumab with or without chemotherapy for 1L treatment in KRAS G12C-mutant advanced NSCLC.

Org: Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Medicine, Division of Hematology Oncology, University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy, Department of Pulmonology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, Netherlands, Institut du Thorax Curie Montsouris, Institut Curie, Paris, and UVSQ, Paris Saclay University, Versailles, France,

Abstract

Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations.

Org: Boehringer Ingelheim (Canada) Ltd,

Abstract

Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799.

Org: LungenClinic, N.N. Blokhin Russian Cancer Research Center, N.N. Petrov National Medical Research Center of Oncology, Thoracic Oncology Unit, Mid North Coast Cancer Institute,

Abstract

Safety and efficacy of complement factor H (CFH) inhibitor GT103 in advanced non-small cell lung cancer (NSCLC): Results of a phase Ib first in human dose escalation study.

Org: Celebration, FL,

Abstract

PEMDA-HN, an open-label, phase II, randomized controlled study of danvatirsen plus pembrolizumab compared to pembrolizumab alone in first-line recurrent and/or metastatic head and neck squamous cell carcinoma (RM HNSCC).

Org: Stathmi, Inc.,

Abstract

Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.

Org: IDIBELL Medical Oncology,

Abstract

Comparison of pembrolizumab plus chemotherapy versus concurrent or sequential radiochemotherapy in patients with driver mutation-lacking lung adenocarcinoma presenting with recurrent laryngeal nerve invasion leading to hoarseness.

Org: Jiangmen, China,

Abstract

Cost effectiveness analysis of nadofaragene firadenovec for the treatment of high-risk, bacillus Calmette-Guerin–unresponsive, non-muscle invasive bladder cancer from a US third-party payer perspective.

Org: Analysis Group Inc.,

Abstract

Phase I/II trial of healthy donor fecal microbiota transplant (hdFMT) in PD-1 relapsed/refractory (R/R) non-small cell lung cancer (NSCLC).

Org: Center for Cancer Research, NCI/NIH,

Abstract

Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of cisplatin (cis)-eligible population from EV-302/KEYNOTE-A39.

Org: Barts Cancer Centre, QMUL, London, United Kingdom, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center; Weill Cornell Medical College, New York, NY, Integrated Cancer Center Ghent, AZ Maria Middelares, Ghent and Center for Oncological Research (CORE), Integrated Personalised and Precision Oncology Network (IPPON), University of Antwerp, Antwerp, Belgium, Charing Cross Hospital, London, United Kingdom, University of California, Los Angeles Medical Center, Los Angeles, CA,

Abstract

Preliminary antitumor activity of COM701 in combination with COM902 and pembrolizumab in patients with MSS-CRC and liver metastases.

Org: Compugen Ltd., Compugen USA Inc.,

Abstract

Phase II study of combination of radiotherapy with pembrolizumab plus chemotherapy in patients with previously untreated metastatic non-small cell lung cancer: North Japan Lung Cancer Study Group 1902.

Org: Omagari Kosei Medical Center, Daisen, Japan, Sendai, Japan, Hirosaki University Graduate School of Medicine, Hirosaki, Japan,

Abstract

Primary immunotherapy monotherapy (PRIMO) in locally advanced cutaneous squamous cell carcinoma.

Org: Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,

Abstract

Triage of advanced cervical cancer through immunotherapy induction (TRACTION).

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,

Abstract

Final analysis of SCARLET study: A single-arm, phase II study of sotorasib plus carboplatin-pemetrexed in patients with advanced non-squamous, non-small cell lung cancer KRAS G12C mutation.

Org: Wakayama Medical University Hospital, Wakayama-Shi, NA, Japan, Department of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan, Kurume University School of Medicine, Fukuoka, Japan, Department of Respiratory and Allergy Medicine, Nagoya City University Hospital, Nagoya, Japan, Kitakyushu Municipal Medical Center, Kitakyushu, Japan,

Abstract

A phase 1b study of tbio-4101 (autologous selected and expanded tumor-infiltrating lymphocytes [TILs]) with pembrolizumab in patients with anti-PD-1–resistant, advanced head and neck squamous cell carcinoma (aHNSCC).

Org: Moffitt Cancer Center, Turnstone Biologics, H. Lee Moffitt Cancer Center and Research Institute,

Abstract

Real-world comparison: Neoadjuvant pembrolizumab (pembro-NACT) vs. dose-dense neoadjuvant chemotherapy (ddNACT) in early stage triple-negative breast cancer (TNBC).

Org: Zucker School of Medicine,

Abstract

Financial impact of fixed-dose versus weight-based dosing approaches for pembrolizumab and nivolumab in the Oncology Care Model for The US Oncology Network (The Network).

Org: McKesson, The US Oncology Network, The Woodlands, TX,

Abstract

A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer.

Org: NCIC Clinical Trials Group,

Abstract

Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC).

Org: Genentech, Roche Products Ltd., F. Hoffmann-La Roche Ltd,

Abstract

Comparative analysis of Keynote522 treatment outcomes in Hispanic versus non-Hispanic patients with breast cancer: A single tertiary center experience.

Org: Joe R. & Teresa Lozano Long School of Medicine, University of Texas Health and Science Center at San Antonio,

Abstract

Toxicity of weight-based vs. flat dosing for immune checkpoint inhibitors in patients with low weight: Retrospective analysis from a tertiary care center.

Org: Chardon, OH, Cancer Informatics,

Abstract

LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.

Org: Franciscan Health Indianapolis,

Abstract

Real life data of KEYNOTE 522: The Cleveland Clinic experience.

Org: Cleveland Clinic Akron General, Department of Translational Hematology and Oncology Research, Lerner Research Institute, Cleveland Clinic Moll Cancer Center at Fairview,

Abstract

Evaluation of the immune landscape associated with the efficacy of immunotherapy in patients with triple-negative breast cancer: Starlet study, synergy between research and clinical work.

Org: Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS Reggio Emilia, Reggio Emilia, Italy, Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Laboratory of Translational Research, Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Breast Surgery Unit, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy, Medical Oncology, Comprehensive Cancer Centre, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy,

Abstract

INTerpath-001: Pembrolizumab with V940 (mRNA-4157) versus pembrolizumab with placebo for adjuvant treatment of high-risk stage II-IV melanoma.

Org: Sydney Medical School,

Abstract

Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.

Org: Gent University Hospital,

Abstract

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.

Org: Universty of Iowa Holden Comprehensive Cancer Center, Jesse Brown VA Medical Center, VA Nebraska Western Iowa Health Care System,

Abstract

The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

Org: The Netherlands Cancer Institute, Amsterdam UMC, VU University Medical Center, Amsterdam, Netherlands, Cancer Center Amsterdam, University Medical Center Groningen, Leiden University Medical Center,

Abstract

Randomized phase II trial of pembrolizumab/lenvatinib (P+L) +/- responder fecal microbiota transplant (R-FMT) in PD-1 relapsed/refractory (R/R) cutaneous melanoma (MEL).

Org: UPMC Hillman Cancer Center, University of Pittsburgh, University of Pittsburgh Medical Center (UPMC), Nihon Medi-Physics,

Abstract

Neoadjuvant pembrolizumab and lenvatinib in resectable mucosal melanoma: NeoPlus study update.

Org: Department of Genitourinary Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, China, Department of Melanoma and Sarcoma, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Haidian District, China,

Abstract

Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.

Org: Niterói, Acre Federal University, Federal University of Santa Catarina, Florianopolis, Viçosa Federal University,

Abstract

Increased risk of hyperglycemia in patients with advanced urothelial cancer treated with enfortumab vedotin: A systematic review and meta-analysis.

Org: Renaissance School of Medicine at Stony Brook University,

Abstract

Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

Org: Netherlands Cancer Institute (NKI-AVL), The Netherlands Cancer Institute, Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals,

Abstract

Costs associated with novel first-line (1L) treatments in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) from a United States (US) Medicare and commercial payer perspective.

Org: EMD Serono Research & Development Institute, Evidera, Inc, The Healthcare Business of Merck KGaA, Darmstadt, Germany,

Abstract

Real-world outcomes of combined lenvatinib and anti-PD-1 in advanced melanoma: Lenvamel, a multicenter retrospective study of the French Group of Skin Cancers.

Org: Service de dermatologie, CHU de Nice, Nice, France, Service de Dermatologie, Centre Hospitalier Universitaire and Université Franche Comté, Inserm 1098 RIGHT, Besançon, France, Hôpital Avicenne – APHP, Bobigny, France, Service de Dermatologie, Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France, Service de Dermatologie, CHU Bordeaux, Bordeaux, France,

Abstract

Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response.

Org: Memorial Sloan Kettering Cancer Center, Division of Early Drug Development for Innovative Therapies, IEO, European Institute of Oncology IRCCS, European Institute of Oncology IRCCS, Breast Service, Department of Surgery, Oncology and Gastroenterology, University of Padova, Oncology 2, IOV - Istituto Oncologico Veneto IRCCS -IOV,

Abstract

Correlative and spatial biomarker analysis of a phase 1/2b study to evaluate pepinemab in combination with pembrolizumab for first-line treatment of patients with recurrent or metastatic head and neck cancer.

Org: Vaccinex, Inc, Zuckerberg Cancer Center, California Cancer Associates for Research and Excellence, Cancer Care of Western North Carolina,

Abstract

Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.

Org: Department II of Interventional Radiology,

Abstract

Analysis of neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma using the SWOG S1801 event-free survival definition.

Org: A.C. Camargo Cancer Center, São Paulo, Brazil,

Abstract

Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.

Org: Yamaguchi University Hospital, Fundación Arturo López Pérez, Fred Hutchinson Cancer Center and University of Washington, Life Groenkloof Hospital, Istinye University Liv Hospital,

Abstract

BCMA-directed CART therapy in patients with multiple myeloma and CNS involvement.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, H. Lee Moffitt Cancer Center and Research Institute, University of Pennsylvania, Hospital of the University of Pennsylvania, University of California, San Francisco,

Abstract

Exploring the role of pembrolizumab in mesothelioma: A single-arm analysis of available data.

Org: Nishtar Medical University Multan Pakistan, Lahore General Hospital Pakistan,

Abstract

A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou Anjie Biomedical Technology Co. Ltd,

Abstract

With eyes on the future: Prospective evaluation of immune-related adverse events in patients with lung cancer.

Org: Hospital das Clinicas UFMG,

Abstract

Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.

Org: Saint John of God Subiaco Hospital,

Abstract

Org: West Virginia University Camden Clark Medical Center, Morgantown, WVU Camden Clark Medical Center,

Abstract

Correlation of baseline ENPP1 and cGAS expression in advanced solid tumors with intratumoral immune activation and clinical outcomes after treatment with the first-in-class oral ENPP1 inhibitor RBS2418, alone or in combination with pembrolizumab.

Org: HonorHealth Research and Innovation Institute, Center for Cancer and Blood Disorders, Med Onc / Hem Consultants,

Abstract

Biomarkers associated with outcomes from KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) versus next-generation hormonal agent (NHA) in previously treated metastatic castration-resistant prostate cancer (mCRPC).

Org: Severance Hospital Yonsei University Health System, University of Auckland, Center for Clinical Cancer and Immunology Trials, Paracelsus Medical University Salzburg, National Yang Ming Chiao Tung University,

Abstract

Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, IRCCS San Raffaele Hospital, Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele,

Abstract

Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.

Org: AZ Sint-Augustinus,

Abstract

WDR4 as a potential indicator of clinical prognosis and immunotherapy in hepatocellular carcinoma.

Org: Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province,

Abstract

Systemic treatments in favorable and very favorable risk metastatic renal cell carcinoma (mRCC): Real world evidence from the International mRCC Database Consortium (IMDC).

Org: Alberta, Canada, Sunnybrook Odette Cancer Centre,

Abstract

Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).

Org: Medical Oncology, Vall d'Hebron Institute of Oncology, Division of Medical Oncology, National Cancer Centre Singapore,

Abstract

Developing behavioral intervention to support molecular testing of patients with biliary tract cancer.

Org: Georgetown University, Lombardi Comprehensive Cancer Center, Lewis Katz School of Medicine, Center for Discovery & Innovation, Hackensack Meridian Health,

Abstract

Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.

Org: Hospital 9 de Julho, Hospital Santa Paula, Clínica AMO, Instituto do Câncer do Ceara,

Abstract

Phase 1b study of futibatinib plus pembrolizumab with or without chemotherapy in patients with esophageal carcinoma: Updated results of antitumor activity.

Org: Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan, Department of Gastroenterological and Pediatric Surgery, Gifu University Hospital, Gifu-Shi, Japan, Department of Gastroenterological Surgery, Tokai University School of Medicine, Isehara, Japan, Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan, Department of Surgery, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki-Shi, Japan,

Abstract

Retro TIMing: A multicentric retrospective analysis of immunotherapy timing in metastatic melanoma.

Org: Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal, Unidade Local de Saúde de Santo António,

Abstract

A signal-finding study of nivolumab and relatlimab in patients with advanced chordoma.

Org: Division of Hematology and Oncology, UCLA Department of Medicine, Los Angeles, CA, Division of Hematology and Medical Oncology, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Departments of Pediatrics and Orthopaedic Surgery, David Geffen School of Medicine, University of California Los Angeles, Cumming School of Medicine, Department of Surgery, Orthopedic Surgery, Calgary, Department of Orthopedic Surgery, UCLA,

Abstract

Use of histologic and immunologic factors in sarcoma to predict response rates to immunotherapy.

Org: Stanford Cancer Institute, Stanford Cancer Center,

Abstract

A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.

Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cleveland Clinic Taussig Cancer Instititute, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD,

Abstract

The impact of body mass index (BMI) on overall survival (OS) among patients receiving immune checkpoint inhibitors (ICIs): A population-based study.

Org: Inst for Clinical Evaluative Sci,

Abstract

A single institution review of immunotherapy use, adverse events, and outcomes in early-onset cancer.

Org: University Hospitals Cleveland Medical Center, University Hospitals Seidman Cancer Center, University Hospitals Center for Clinical Research, Case Western Reserve University School of Medicine, University Hospitals Sussex NHS Foundation Trust,

Abstract

Exploring systemic treatment approaches for advanced pure large cell neuroendocrine carcinoma (LCNEC): A multicenter retrospective analysis.

Org: Bio-Medico Campus University Hospital,

Abstract

Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).

Org: PRECISIONheor,

Abstract

Predictive markers of complete pathological response to neoadjuvant chemo-immunotherapy in triple negative breast cancer.

Org: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Institute of Oncology Ljubljana,

Abstract

Overlapping and non-overlapping indications for checkpoint inhibitors in the US.

Org: Brigham and Women's Hospital, Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, Memorial Sloan Kettering Cancer Center,

Abstract

Timing of immunotherapy in stage IV non-small cell lung cancer.

Org: Department of Thoracic and Breast Surgery, Oita University Faculty of Medicine, Yufu, Japan, Penn State Health Milton S. Hershey Medical Center,

Abstract

A descriptive patient-reported outcomes (PROs) analysis of KEYNOTE-412 to understand head and neck symptom burden.

Org: Merck & Co., Inc., Gustave Roussy Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Yale University School of Medicine, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

Phase 2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 (trastuzumab imbotolimod) +/- pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (T-DXd).

Org: Stanford University Medical Center, University of Miami Health System, Stanford University School of Medicine, Medical Oncology Department, Ramón y Cajal University Hospital, Levine Cancer Institute, Atrium Heath,

Abstract

Soluble mesothelin neutralizes mesothelin antibody-based therapies.

Org: Mayo Clinic, National Cancer Institute, Vilnius, Lithuania,

Abstract

Association of ephrinB2 (B2) expression on overall survival (OS) and resistance to PD1/L1 inhibitors (inh) in metastatic urothelial carcinoma (mUC).

Org: Vasgene Therapeutics, Inc, Newark, NJ, Orlando, FL,

Abstract

Interrogating the tumor microenvironment (TME) in patients (pts) with head and neck mucosal squamous cell carcinoma (HNmSCC) treated with programmed death-1 (PD-1) inhibitors.

Org: Centenary Institute, Sydney University,

Abstract

Linking the companion diagnostic function of cancer genome profiling to therapy: Investigation of TMB-high predictors.

Org: Hiroshima Prefectural Hospital, Hiroshima City North Medical Center Asa Citizens Hospital, JA Onomichi General Hospital, JA Hiroshima General Hospital,

Abstract

Pre-treatment immune biomarkers of pembrolizumab efficacy in patients with glioblastoma treated with standard of care.

Org: Baylor College of Medicine, Oregon Health & Science University, Oregon Healthy Authority Health Promotion and Chronic Disease Prevention Section, Lake Oswego, OR, Providence Brain and Spine Institute,

Abstract

Real world impact of pembrolizumab availability for deficient mismatch repair metastatic colorectal cancer.

Org: Ballarat Health Services, Royal Hobart Hospital, South West Regional Cancer Centre, Cairns and Hinterland Health,

Abstract

Endogenous retrotransposable elements as a novel predictive biomarker of response to immunotherapy.

Org: Princess Alexandra Hospital & University of CanadaQueensland,

Abstract

A phase I pilot study of personalized neoantigen peptide-based vaccine in combination with pembrolizumab in advanced solid tumors (PNeoVCA).

Org: Mayo Clinic Florida, Mayo Clinic,

Abstract

Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.

Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,

Abstract

Comparative analysis of pembrolizumab and cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma: Real-world data.

Org: Massey Comprehensive Cancer Center, Division of Hematology, Oncology, and Palliative Care,

Abstract

Effect of a novel anti-PD-1-proIL-2 bifunctional fusion protein on potent anti-tumor activity via PD-1 checkpoint inhibition and conditional IL-2R agonism.

Org: Proviva Therapeutics, Bedford, MA, Shanghai, China, Gracell Biotechnologies, Ltd.,

Abstract

Combining nimotuzumab with PD-L1 inhibitors and chemotherapy to treat esophageal cancer: A retrospective study.

Org: First Affiliated Hospital of Guangdong Pharmaceutical University,

Abstract

Cost analysis of targeted and immunotherapies in operable esophageal and non-small cell lung cancers.

Org: Division of General Thoracic Surgery, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery,

Abstract

Correlation between metastatic site and immunotherapy efficacy in patients with advanced dMMR/MSI colorectal cancer: Real-World Italian multicentric retrospective study (Colon-MSI).

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy, Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milano, Italy, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Correlation between irAEs and treatment efficacy of anti-PD-1 single agent in patients with recurrent/metastatic head and neck squamous cell carcinoma: A monocentric real-world observational study.

Org: IOV – IRCCS,

Abstract

Use of immunotherapy with check point inhibitors in soft tissue sarcoma: Analysis from single institution.

Org: University of Louisville, James Graham Brown Cancer Center,

Abstract

Phase II trial assessing safety, efficacy and immune correlates of heterologous prime-boost with pBI-11 (IM) and TA-HPV (IM) plus pembrolizumab for advanced, PD-L1 CPS≥1, hrHPV+ oropharyngeal cancer.

Org: Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Johns Hopkins University Bloomberg School of Public Health,

Abstract

Efficacy and safety of sintilimab plus paclitaxel and cisplatin as neoadjuvant therapy for locally advanced cervical cancer: A phase II trial.

Org: Sun Yet Sen University Cancer Center,

Abstract

Neoadjuvant immune checkpoint blockade in mismatch repair deficient endometrial cancer: An update on recurrence-free survival and correlative biomarkers.

Org: University Medical Centre Groningen, University Hospital Zurich, Department of Pathology and Molecular Pathology, Department of Pathology, University Medical Center Groningen,

Abstract

Patterns of pembrolizumab use for recurrent cervical cancer.

Org: Columbia University Medical Center, Merck & Co., Inc., Herbert Irving Comprehensive Cancer Center,

Abstract

Cost-efficiency and expanded access modeling of toripalimab versus pembrolizumab in locally advanced or metastatic nonsquamous non-small cell lung cancer.

Org: Matrix45 LLC, Coherus Biosciences, University of Arizona of Pharmacy, Center for Health Outcomes and PharmacoEconomic Research, University of Arizona Cancer Center,

Abstract

Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).

Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,

Abstract

Oral cyclophosphamide plus bevacizumab in recurrent ovarian, fallopian tube and primary peritoneal cancer.

Org: University of Texas Medical Branch at Galveston, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,

Abstract

Systematic literature review and network meta-analysis of first-line therapies for locally advanced/metastatic urothelial carcinoma.

Org: Curta Inc.,

Abstract

Survival differences in advanced non-small cell lung cancer after developments in regimens with immune check point inhibitors: Population based retrospective study from United States SEER database.

Org: Montgomery Regional Medical Campus,

Abstract

First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.

Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,

Abstract

Cognitive symptoms in patients with cancer receiving PD-1/PD-L1 checkpoint inhibitors: Insights from a cross-sectional pilot study.

Org: University of Connecticut Internal Medicine Residency Program, University of Connecticut Health Center,

Abstract

Blood based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage non-small cell lung cancer: The IOpener study.

Org: Radbound University Medical Center, Elisabeth Tweesteden Hospital, Diakonessenhuis, PamGene International B.V., Amsterdam Medical Center,

Abstract

Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.

Org: Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, Royal Brisbane and Women's Hospital, Herston, and University of Queensland, Brisbane, Australia, CHRU Lille - Hôpital Claude Huriez, Lille, France, Aix-Marseille University, Hôpital de la Timone, Marseille, France, Johannes Wesling Medical Center, Ruhr University Bochum, Minden, Germany,

Abstract

Comparative efficacy of six programmed cell death protein-1 inhibitors in first-line treatment for advanced non-small cell lung cancer: A retrospective cohort study.

Org: Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital,

Abstract

Predictive cytokine biomarkers for immune-related adverse events associated with immune checkpoint inhibitor therapy in Hodgkin lymphoma.

Org: NYU Langone Medical Center, NYU Langone Health, New York, NY, Perlmutter Cancer Center, New York University Langone Health,

Abstract

Economic evaluation of the novel PD-1 inhibitor toripalimab in recurrent or metastatic nasopharyngeal carcinoma: Cost-efficiency and expanded access modeling versus pembrolizumab.

Org: Matrix45 LLC,

Abstract

A multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of YH003 in combination with pembrolizumab and nab-paclitaxel in the first-line treatment of patients with unresectable/metastatic mucosal melanoma.

Org: Fujian Cancer Hospital, Sun Yat-sen University Cancer Center Gansu Hospital, West China Hospital, Union Hospital, Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine, Changsha, China,

Abstract

Intravesical local administration of pembrolizumab for treatment of bladder cancer: A novel strategy to minimize toxicity.

Org: Michigan Institute of Urology,

Abstract

Efficacy and safety of PARP inhibitors (PARPi) with immune checkpoint inhibitors (ICI) in metastatic castration-resistant prostate cancer (mCRPC): A systematic review and single-arm meta-analysis.

Org: Hospital do Servidor Público do Estado de São Paulo, Faculdade de Medicina de Barbacena FAME - FUNJOB, Centro de Oncologia do Paraná,

Clinical trial

The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma

Status: Completed, Estimated PCD: 2021-12-30

Abstract

A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec (VO) combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).

Org: UPMC Hillman Cancer Center, Pittsburgh, PA, Replimune, Inc., Woburn, MA, Gustave Roussy and Paris-Saclay University,

Abstract

Health outcomes of pembrolizumab plus chemotherapy in non-small cell lung cancer.

Org: Jaén, Spain, Jaen, Spain,

Abstract

Weekly paclitaxel (P), carboplatin (CP) plus pembrolizumab (PMB) as first-line treatment of recurrent or metastatic (R/M) or locally very advanced (LVA) head and neck squamous cell carcinoma (HNSCC): A retrospective study in 39 patients (pts).

Org: Institut de Cancérologie Strasbourg Europe,

Abstract

KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors.

Org: MSD (China) Co., Ltd., Shanghai, China, MSD (China) Co., Ltd., Beijing, China,

Abstract

Response rate with cetuximab used less than 3 months after immunotherapy (IO) for recurrent/metastatic head and neck squamous cell carcinomas (R/M HNSCC) compared to larger delay.

Org: Owkin France, Centre Leon Berad,

Abstract

Characterizing the tumor and immune landscape of patients with melanoma treated with combined checkpoint blockade and MAPK-targeted therapy.

Org: Division of Oncology, Rambam health care, Haifa, Israel, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Division of Biostatistics, Department of Data Science, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel,

Abstract

STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.

Org: Seattle Children’s Research Institute, Seattle Childrens Research Institute,

Abstract

Neoadjuvant pembrolizumab/nab-paclitaxel/cisplatin in patients with locally advanced head and neck squamous cell carcinoma: A single-arm phase II study.

Org: Guangdong Provincial People‘s Hospital,

Abstract

A retrospective study of first line atezolizumab-carboplatin-etoposide in extensive-stage small cell lung cancer: Real world data from a Spanish tertiary center.

Org: Department of Medical Oncology, Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology. Hospital universitario de Cruces, Barakaldo, Spain, Department of Medical Oncology. Hospital Universitario Cruces, Barakaldo, Spain, Deparment of Medical Oncology. Cruces University Hospital, Barakaldo, Spain, Department of Medical Oncology of Cruces University Hospital, Barakaldo, Spain,

Abstract

Efficacy and safety of sigvotatug vedotin, an investigational ADC, in NSCLC: Updated phase 1 results (SGNB6A-001).

Org: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, The Royal Marsden Hospital (Surrey), London, United Kingdom, Beth Israel Deaconess Medical Center, Boston, MA, Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona, Orlando, FL, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR,

Abstract

A phase II trial of pembrolizumab plus platinum-based chemotherapy as first-line systemic therapy in advanced penile cancer: HERCULES (LACOG 0218) trial.

Org: Hospital Universitário de Brasília, Fundação Amaral Carvalho, Instituto Nacional do Câncer (INCA), Oncológica do Brasil, BP - Beneficência Portuguesa de São Paulo,

Abstract

Long term outcomes in patients with recurrent/metastatic (R/M) salivary gland cancer (SGC) treated with immune checkpoint inhibitors (ICI).

Org: Fred Hutchinson Cancer Center, Seattle, WA, University of Washington and Fred Hutchinson Cancer Research Centre, Division of Hematopathology, Mayo Clinic, Rochester, MN, Virginia Commonwealth University School of Medicine,

Abstract

Real world data of safety of immune-checkpoint inhibitors in patient with cancer at tertiary care hospital in Saudi Arabia.

Org: Clinical Pharmacy Department, King Fahad Medical City,

Abstract

Org: Knapp Center for Biomedical Discovery, Centre Hospitalier de Universite de Montréal, Zentralklinik Bad Berka GmbH, HIA Sainte-Anne, École de Val de Grace,

Abstract

A phase 2 study of de-escalation in resectable, locally advanced cutaneous squamous cell carcinoma (cSCC) with the use of neoadjuvant pembrolizumab: De-Squamate.

Org: Princess Alexandra Hospital and Faculty of Medicine at University of Queensland, Royal Brisbane & Womens Hospital,

Abstract

Induction immunotherapy-based regimens followed by palliative CCRT may lead to conversion surgery in selected patients and boost survival for stage IV ESCC.

Org: National Taiwan University Hospital Yunlin Branch, Yunlin, Yun-lin Branch, Yunlin County,

Abstract

Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC.

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr Kommunarka Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Cancer Research Center of the Ministry of Healthcare of the Russian Federation, Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology, Clinical and Scientific Research Practical Oncological Center, Saint Petersburg Scientific Practical Center of Specialized Kinds of Medical Care,

Abstract

Changing treatment patterns for hepatocellular carcinoma: A SEER-Medicare study.

Org: Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, Dana Farber Cancer Institute, Boston, MA, Dana-Farber Cancer Institute, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

Cardiomyopathy among recipients of immune checkpoint inhibitor therapy: A prospective study.

Org: Division of Cardiovascular Imaging, St. Francis Hospital & Heart Center, DeMatteis Cardiovascular Institute of St. Francis Hospital, Cardio-Oncology Service, Cardiology Division,

Abstract

First results of the NOGGO PERCEPTION: Phase II investigational study of pembrolizumab in combination with chemotherapy in platinum-sensitive recurrent low-grade serous ovarian cancer.

Org: North-Eastern German Society of Gynaecological Oncology (NOGGO), Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Campus Virchow Klinikum, Berlin, Germany, North-Eastern-German Society of Gynaecological Oncology, Berlin, Germany, Kliniken Essen-Mitte, Department of Gynecology and Gynecological Oncology, Essen, Germany, Charité Universitätsmedizin Berlin and North Eastern German Society for Gynecologic Oncology (NOGGO), Berlin, Germany,

Abstract

Effectiveness of adjuvant immunotherapy in muscle-invasive urothelial cancer: A systematic review and meta-analysis of randomized controlled trials.

Org: Federal University of São João Del-rei, Divinópolis, Brazil, Divinópolis, Brazil, Brazil, Federal University of Rio Grande do Norte, Natal,

Abstract

Survival outcomes of patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with platinum-based chemotherapy plus paclitaxel after anti-PD-1 monotherapy.

Org: Case Western Reserve School of Medicine, Cleveland, OH, Case Western Reserve University School of Medicine,

Abstract

PD-1 inhibitors versus conventional therapies for adjuvant treatment of resected acral melanoma: A systematic review and meta-analysis.

Org: Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Fudan University (Xiamen Branch), Department of Musculoskeletal Oncology, the First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Petosemtamab (MCLA-158) with pembrolizumab as first-line (1L) treatment of recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC): Phase 2 study.

Org: Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quirón, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, FL, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain, Sarah Cannon Research Institute UK, London, United Kingdom, Florida Cancer Specialists and Research Institute, Lakewood Ranch, FL,

Abstract

Brain metastases in patients with pleural mesothelioma receiving dual checkpoint blockade compared to single-agent checkpoint blockade or chemotherapy.

Org: Hospital of the University of Pennsylvania, Perelman School of Medicine, Penn Medicine at Lancaster General Health, University of Pennsylvania, Abramson Cancer Center,

Abstract

Case series: Outcomes of immunotherapy in locally advanced and metastatic cutaneous squamous cell carcinoma in Lakes and Waikato region.

Org: Waikato Hospital, Te Whatu Ora Lakes,

Clinical trial

A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Status: Active (not recruiting), Estimated PCD: 2025-04-30

Clinical trial

A Phase II Study of LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Status: Terminated, Estimated PCD: 2020-06-17

Clinical trial

A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status: Active (not recruiting), Estimated PCD: 2024-08-01

Clinical trial

A Clinical Trial of Pembrolizumab in Patients With Hepatitis B Virus-related Hepatocellular Carcinoma, With Parallel Study on Baseline and Serial Change in the Immune Environment

Status: Active (not recruiting), Estimated PCD: 2024-12-30

Clinical trial

Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Status: Recruiting, Estimated PCD: 2024-08-01

Clinical trial

Immunotherapy in Combination With PARP Inhibition in Advanced Cervical Cancer Patients Functionally Competent or Deficient for the Fanconi Anemia Repair Pathway

Status: Active (not recruiting), Estimated PCD: 2030-11-01

Clinical trial

A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas

Status: Completed, Estimated PCD: 2024-04-15

Clinical trial

Phase I/IIa Clinical Trial to Assess the Maximum Tolerated Dose (MTD), Safety, and the Anti-tumor Effect of TB511 Monotherapy and Pembrolizumab Combination Therapy in Patients With Advanced Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2025-03-01

Clinical trial

First-line Carboplatin/Paclitaxel/Lenvatinib/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas

Status: Recruiting, Estimated PCD: 2025-12-31

Clinical trial

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Status: Recruiting, Estimated PCD: 2040-06-01

Clinical trial

A Phase II Sequential Window of Opportunity Trial of Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

Status: Not yet recruiting, Estimated PCD: 2025-12-01

Clinical trial

A Phase I/II Study of Blinatumomab in Combination With Pembrolizumab (MK-3475) for Adults With Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia With High Bone Marrow Lymphoblast Percentage

Status: Active (not recruiting), Estimated PCD: 2025-12-31

Clinical trial

A Multi-centre Phase II Study to Determine the Response Kinetics, Safety and Efficacy of Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma Considered Unsuitable for ABVD

Status: Active (not recruiting), Estimated PCD: 2023-02-16

Clinical trial

A Multicenter, Randomized, Double-Blind, Phase 2, Basket Study of MK-4280A, a Coformulation of Favezelimab (MK-4280) With Pembrolizumab (MK-3475) in Selected Solid Tumors (KeyForm-010)

Status: Recruiting, Estimated PCD: 2027-03-09

Clinical trial

Autologous Activated T-Cells Transduced With A 3rd Generation GD-2 Chimeric Antigen Receptor And iCaspase9 Safety Switch Administered To Patients With Relapsed Or Refractory Neuroblastoma (GRAIN)

Status: Active (not recruiting), Estimated PCD: 2015-12-01

Clinical trial

A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

Status: Active (not recruiting), Estimated PCD: 2024-02-14

Clinical trial

Efficacy and Safety of Albumin-bound Paclitaxel-Lenvatinib-Pembrolizumab in Advanced Nonsquamous NSCLC Patients After Progression to First-line Anti-PD-1/L1 Inhibitor With Platinum-doublet Chemotherapy

Status: Not yet recruiting, Estimated PCD: 2024-10-01

Clinical trial

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Status: Recruiting, Estimated PCD: 2028-04-19

Clinical trial

A Phase Ib/II Randomised Open Label Study of BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib Compared to Pembrolizumab or Dabrafenib/Trametinib Alone, in Patients With Advanced Non-resectable (Stage IIIc) or Metastatic (Stage IV) Melanoma

Status: Active (not recruiting), Estimated PCD: 2024-06-01

Clinical trial

A Phase II Trial of Pembrolizumab in Patients With Non-small Cell Lung Cancer and a Performance Status of 2

Status: Active (not recruiting), Estimated PCD: 2023-02-07

Clinical trial

Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer

Status: Completed, Estimated PCD: 2022-06-01

Clinical trial

ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation

Status: Not yet recruiting, Estimated PCD: 2028-12-01

Clinical trial

Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System Post PD1 Exposure: Phase II Trial

Status: Withdrawn, Estimated PCD: 2025-07-01

Clinical trial

An Open-label Phase II Study of Pembrolizumab in East Asian Patients With Advanced/Metastatic Acral Lentiginous Melanoma

Status: Completed, Estimated PCD: 2022-02-28

Clinical trial

A Phase I/II Trial of Pembrolizumab (MK-3475) and Poly-ICLC in Patients With Metastatic Mismatch Repair-proficient (MRP) Colon Cancer

Status: Completed, Estimated PCD: 2022-07-29

Clinical trial

Phase 2 Study of Azacitidine in Combination With Pembrolizumab in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients and in Newly Diagnosed Older (≥65 Years) AML Patients

Status: Completed, Estimated PCD: 2022-04-01

Clinical trial

A Phase II Trial of Reirradiation Combined With Open Label Pembrolizumab in Patients With Locoregional Inoperable Recurrence or Second Primary Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Status: Active (not recruiting), Estimated PCD: 2023-08-31

Clinical trial

An Exploratory Study to Investigate the Immunomodulatory Activity of Radiation Therapy (RT) in Combination With MK-3475 in Patients With Recurrent/Metastatic Head and Neck, Renal Cell Cancer, Melanoma and Lung Cancer

Status: Completed, Estimated PCD: 2018-06-05

Clinical trial

Phase II Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Status: Completed, Estimated PCD: 2021-12-01

Abstract

Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.

Org: Stephenson Cancer Center, The Tisch Cancer Institute, Mayo Clinic Cancer Center Scottsdale, The University of Arizona Cancer Center, City of Hope Comprehensive Cancer Center,

Abstract

Exploratory biomarker analysis of the phase 3 KEYNOTE-604 study of pembrolizumab plus etoposide for extensive-stage SCLC.

Org: Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea, Memorial Sloan Kettering Cancer Center, Vall d’Hebron University Hospital/VHIO, Lausanne University Hospital, William Osler Health System,

Abstract

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.

Org: Vanderbilt-Ingram Cancer Center, Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital With Outpatient Clinic, Centre Hospitalier de l’Université de Montréal, Hospital de Clínicas de Porto Alegre,

Abstract

Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.

Org: Flatiron Health, San Francisco, CA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Flatiron Health, New York, NY, Flatiron Health, Dallas, TX,

Abstract

Phase 3 randomized study for evaluation of physician choice Rx and triple metronomic as second-line therapy in head and neck cancer (CRSF 2021-HN-001).

Org: Narayana Multispeciality Hospital, Tata Memorial Hospital, Homi Bhabha cancer hospital and research centre, Regency Hospital, National Cancer Insitute,

Abstract

Phase II trial of pembrolizumab in patients with brain metastases.

Org: Massachusetts General Hospital and Harvard Medical School, Dana-Farber Cancer Institute, Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, Yale University,

Abstract

KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Org: University of Arizona College of Medicine, European Institute of Oncology IRCCS, University of California Irvine, GINECO-Centre Jean Perrin, Clermont-Ferrand, France, Saitama Medical University International Medical Center,

Abstract

ImmunoSarc2: A Spanish Sarcoma Group (GEIS) phase Ib trial of doxorubicin and dacarbazine plus nivolumab in first line treatment of advanced leiomyosarcoma.

Org: Medical Oncology Department, Institute of Biomedicine of Seville, Hospital Universitario y Politécnico La Fe, Son Espases University Hospital, University Hospital Virgen del Rocio,

Abstract

Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study.

Org: National Taiwan University Hospital and National Taiwan University Cancer Center, Seoul National University Bundang Hospital, Istituto Europeo di Oncologia, Osaka International Cancer Institute, Osaka, Japan, Peking Union Medical College Hospital,

Abstract

Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma.

Org: Dana-Farber Cancer Institute, UPMC Hillman Cancer Center, Cleveland Clinic Lerner College of Medicine, Princess Margaret Cancer Centre, Moffitt Cancer Center,

Abstract

Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.

Org: The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA, Henry Ford Cancer Institute, Detroit, MI, START San Antonio, San Antonio, TX, University of Florida-Health Cancer Center, Orlando Health, Orlando, FL, MUSC Hollings Cancer Center, Charleston, SC,

Abstract

Differential impact of proliferation signature on efficacy of neoadjuvant chemoimmunotherapy in sTIL-high and sTIL-low triple-negative breast cancer (TNBC): Biomarker analysis of the NeoPACT trial.

Org: University of Kansas Cancer Center, GZA ANTWERP BELGIUM, Texas Oncology, University of Kansas Medical Center, University of Kansas Medical Center Department of Internal Medicine,

Abstract

TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) in advanced non-small cell lung cancer (aNSCLC).

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Cheng Kung University, Daiichi Sankyo Inc., Taichung Veterans General Hospital, Mayo Clinic,

Abstract

Immuno-chemotherapy as single treatment modality for larynx preservation (ICoLP): Co-primary endpoints and safety results.

Org: The University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Thoracic/Head and Neck Medical Oncology, Houston, TX,

Abstract

Org: Asan Medical Center, University of California Los Angeles, University of California Irvine, Hannover Medical School, Zhongshan Hospital,

Abstract

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

Org: Gwangju Institute of Science and Technology (GIST), prismCDX Co., Ltd, Asan Institute for Life Sciences, Department of Pathology, Brigham and Women's Hospital, Harvard Medical School,

Abstract

Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study.

Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario Virgen Macarena, Maria Skłodowska-Curie National Institute of Oncology Center, Poznan University of Medical Sciences and Greater Poland Cancer Center, UPMC Hillman Cancer Center,

Abstract

KEYNOTE-671: Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC.

Org: Department of Medicine, Division of Oncology, Stanford University, Stanford Cancer Institute, Stanford, CA, Centre Hospitalier de l’Universite de Montreal, Montreal, QC, Canada, Kanagawa Cancer Center, Yokohama, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Department of Internal Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking, Beijing, China, Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Pek, Beijing, China, Beijing Cancer Hospital, Beijing, China, University Hospitals Leuven, Leuven, Belgium, Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, Zentralklinik Bad Berka GmbH, Bad Berka, Germany, Sanatorio Parque, Santa Fe, Argentina, HIA SAINTE ANNE, Toulon, France, Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas De Gran Canaria, Spain, Memorial Sloan Kettering Cancer Center, New York, NY, University of Turin, AOU San Luigi Orbassano, Turin, Italy, Merck & Co., Inc., Rahway, NJ, Merck and Co, Inc., Rahway, NJ, Merck & Co., Inc., Kenilworth, NJ, McGill University Health Center, Montreal, QC, Canada,

Abstract

Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial.

Org: Laura and Isaac Perlmutter Cancer Center, Sir Charles Gairdner Hospital, Washington University Oncology, Sarah Cannon Research Institute/Tennessee Oncology, One Clinical Research and Edith Cowan University,

Abstract

Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up.

Org: Cleveland Clinic Lerner College of Medicine, University of California San Diego, Yale Cancer Center, University of California, San Francisco Medical Center, Stanford University School of Medicine, Division of Oncology,

Abstract

First-in-human, phase 1a dose finding of LVGN6051 CD137/4-1BB agonistic antibody with or without pembrolizumab in patients with advanced solid tumors.

Org: Horizon Oncology & Research Center, Merck & Co., Inc., Lyvgen Biopharma Holdings, Department of Investigational Cancer Therapeutics,

Abstract

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial.

Org: Cross Cancer Institute, Assistance Publique Hôpitaux de Marseille (AP-HM), Fondazione IRCCS Istituto Nazionale Tumori, AZ Ospedaliera Villa Scassi, National Cancer Institute of Naples,

Abstract

Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab combined with weekly paclitaxel carboplatin in first-line in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible for cisplatin-based therapies.

Org: Centre Léon Bérard, Centre Paul Strauss, CH Bretagne, Centre Henri Becquerel, Clinique des Ormeaux,

Abstract

A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for patients with dMMR/MSI-H stage III colon cancer.

Org: Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China, Biotherapy Center,

Abstract

Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.

Org: Alberts Cellular Therapy, Department of Medicine, Division of Clinical Haematology, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione G. Pascale, IRCCS, Naples, Italy, Department of Haematology and Transplantology, Medical University of Gdańsk, Smoluchowskiego, Gdańsk, Poland,

Abstract

Long-term follow-up of “adjuvant” pembrolizumab following locally ablative therapy for oligometastatic non-small cell lung cancer.

Org: University of Pennsylvania, Abramson Cancer Center, Penn Presbyterian Medical Center, Perelman School of Medicine,

Abstract

Retrospective clinical analysis of circulating tumor DNA (ctDNA)–based molecular response (MR) and baseline blood-based tumor mutational burden (bTMB) for monitoring response in phase 3 trial of bintrafusp alfa vs. pembrolizumab treatment of non-small cell lung cancer (NSCLC).

Org: Clinical Measurements Sciences, Global Research & Development, EMD Serono Research & Development Institute, Guardant Health Inc., Clinical Biomarkers and Companion Diagnostics,

Abstract

A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

Org: Moffitt Cancer Center, Stanford Cancer Center, Washington University School of Medicine in St Louis, University of Washington and Fred Hutchinson Cancer Research Centre, Massachusetts General Hospital,

Abstract

Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.

Org: Geneos Therapeutics, Johns Hopkins University Bloomberg School of Public Health,

Abstract

EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).

Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,

Abstract

Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC).

Org: Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Hackensack Meridian Health, MedStar Washington Hospital Center,

Abstract

NEOSPACE trial: Neoadjuvant pembrolizumab-gemcitabine-cisplatin followed by concurrent pembrolizumab-chemoradiation and maintenance pembrolizumab for stage IVA nasopharyngeal cancer (NPC).

Org: Department of Clinical Oncology, Prince of Wales Hospital, Shatin, Hong Kong, National Cancer Center of Singapore, Singapore, Department of Chemical Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Imaging and Interventional Radiology, The Chinese University of Hong Kong, Shatin, Hong Kong, Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Shatin, Hong Kong,

Abstract

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with pembrolizumab and carboplatin as first-line treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC): A single-arm, phase 2 trial.

Org: Washington University Siteman Cancer Center, St. Louis, MO, Washington University School of Medicine in St Louis,

Abstract

Safety and efficacy of immune checkpoint inhibitor (ICI) naïve cohort from study of PDS0101 and pembrolizumab in HPV16-positive head and neck squamous cell carcinoma (HNSCC).

Org: PDS Biotechnology, Merck & Co., Inc., Lineberger Comprehensive Cancer Center, University of Michigan Health System Comprehensive Cancer Center, MUSC Hollings Cancer Center, Charleston, SC,

Abstract

A phase 2 study of magrolimab combination therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma: ELEVATE HNSCC.

Org: Stanford Cancer Center, Portuguese Oncology Institute of Porto, Porto, Portugal, The Kinghorn Cancer Centre, CUF Instituto de Oncologia, Macquarie University,

Abstract

Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.

Org: Melanoma Institute Australia, The Netherlands Cancer Institute, Amsterdam University Medical Centers, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, The Christie NHS Foundation Trust,

Abstract

NeoPlus: A phase II study of neoadjuvant lenvatinib and pembrolizumab in resectable mucosal melanoma.

Org: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology,Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, China, Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, China, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Melanoma & Sarcoma,Peking University Cancer Hospital & Institute, Beijing, China,

Abstract

A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.

Org: Sarah Cannon Research Institute at Florida Cancer Specialists, Hackensack Meridian Health, START San Antonio, University of Navarra, Carolina BioOncology Institute,

Abstract

Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Breast Surgical Oncology, St. Luke's International Hospital, Tokyo, Japan, St. Luke's International Hospital, MD Anderson Cancer Center, Department of Thoracic and Head and Neck Medical Oncology,

Abstract

Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.

Org: Department of Medicine, Duke University School of Medicine, Texas Oncology-Baylor Charles A. Sammons Cancer Center, PIH Health Whittier Hospital, Nebraska Hematology-Oncology P.C., Division of Hematology/Oncology, David Geffen School of Medicine at the University of California Los Angeles/Jonsson Comprehensive Cancer Center,

Abstract

NeoIRX trial: Immunologic induction with peri-lymphatic cytokines to enhance pembrolizumab (pembro) response in stage II/III triple-negative breast cancer (TNBC).

Org: Providence Cancer Institute, Oregon Clinic,

Abstract

Immune checkpoint inhibitor (ICI) therapy in glioblastoma: Institutional experience at the Massachusetts General Hospital (MGH).

Org: Massachusetts General Hospital, Stanford Medical Center,

Abstract

A phase 1 dose-escalation study of RiMO-301 with palliative radiation in advanced tumors.

Org: University of Chicago, University of Texas MD Anderson Cancer Center, Department of Hematology Oncology University of Illinois of Chicago College of Medicine, UPMC Hillman Cancer Center, University of Illinois Urbana-Champaign,

Abstract

Efficacy and safety of camrelizumab in combination with radiation and chemotherapy for recurrent or metastatic cervical cancer.

Org: Tianjin Medical University Cancer Hospital & Institute, Tianjin Medical university cancer institute & Hospital, Tianjin Cancer Hospital Airport Hospital,

Abstract

Time-dependent efficacy of immune checkpoint inhibitors in the treatment of metastatic cancers: A meta-analysis.

Org: UPR "Chronotherapy, Cancers and Transplantation", Paris-Saclay University, Villejuif, France, Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, Coventry, United Kingdom, Department of Thoracic and Medical Oncology, Avicenne AP-HP, Université Sorbonne Paris Nord, Bobigny, France,

Abstract

Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline.

Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Milano, Veracyte, Inc., IRCCS Ospedale San Raffaele, Radiology Unit,

Abstract

The study of immune-related adverse events in a community-based centre.

Org: BronxCare Health System, Bronx-Lebanon Hospital Center, BronxCare Mount Sinai Comprehensive Cancer Care,

Abstract

Global circulating free DNA methylation and fragmentome deconvolution in patients with metastatic renal cell carcinoma treated with immunotherapy (GOLDEN).

Org: Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada,

Abstract

Impact of immune checkpoint inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial.

Org: Dana-Farber Cancer Institute, Boston, MA, Brigham and Women's Hospital/Massachusetts General Hospital, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL,

Abstract

Prospective evaluation of pathologic response with neoadjuvant chemo-immunotherapy in metaplastic breast cancer.

Org: Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering - Breast and Imaging Center, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.

Org: University of Chicago, University of Chicago Medicine, Northshore University Health System, University of Chicago Medical Center, Chicago, IL, Section of Hematology/Oncology,

Abstract

Quantifying the growth of clinical actionability in precision oncology using OncoKB.

Org: Memorial Sloan Kettering Cancer Center,

Abstract

The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.

Org: Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Barbara Ann Karmanos Cancer Institute, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,

Abstract

Landmark analysis of OS by response status in previously treated patients (pts) with advanced hepatocellular carcinoma (aHCC): Post hoc analysis of the KEYNOTE-394 study.

Org: MSD China, Merck & Co., Inc.,

Abstract

Phase II clinical trial of olaparib plus pembrolizumab in the treatment of patients with advanced biliary tract cancer.

Org: MedStar Georgetown University Hospital, MedStar Harbor Hospital, Georgetown University Medical School, Georgetown Lombardi Comprehensive Cancer Center, The Ruesch Center for the Cure of Gastrointestinal Cancers,

Abstract

Spatial distribution of B cells and lymphocyte clusters for the treatment of non-small cell lung cancer.

Org: ImaBiotech, Loos, France, ImaBiotech SAS, Loos, France,

Abstract

Clinical and biological activity of FLX475, an oral CCR4 antagonist, in advanced cancer.

Org: RAPT Therapeutics, Johns Hopkins Hospital,

Abstract

Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer.

Org: Gustave Roussy Département d'Organisation du Parcours Patient, La Timone University Hospital of Marseille, Sorbonne University and Saint-Antoine Hospital, Centre GF Leclerc, Institut de Cancerologie de l'Ouest, Saint-Herblain, France,

Abstract

KEYNOTE-905/EV-303: A phase 3 study to evaluate the efficacy and safety of perioperative pembrolizumab or pembrolizumab plus enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC).

Org: Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital and Scientific Institute, Milan, Italy, Eberhard Karls University of Tübingen, Tübingen, Germany, Icahn School of Medicine at Mount Sinai, New York, NY, Carolina Urologic Research Center, Myrtle Beach, SC,

Abstract

Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1.

Org: Early Phase Clinical Trials Unit, START Madrid Fundacion Jimenez Diaz, Vall d’Hebron University Hospital/VHIO, Vall d’Hebron Institute of Oncology (VHIO), University College London Hospital NHS Trust and Great Ormond Street Hospital,

Abstract

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy.

Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, New York, NY, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering/Weill Cornell Medical College,

Abstract

Phase II study of lenvatinib plus pembrolizumab for patients with immunotherapy-naive advanced gastric cancer following first line therapy.

Org: Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, New York, NY, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, Mount Sinai Health System, NY, NY, Mount Sinai Health System, NY, NY, Icahn School of Medicine at Mount Sinai, New York, NY, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY, NYU, New York, NY, NYU Grossman School of Medicine, Department of Population Health, Division of Biostatistics, New York, NY,

Abstract

Genome-wide aneuploidy detected in circulating cell-free DNA of patients with metastatic urothelial cancer as a predictive biomarker of response to pembrolizumab.

Org: Erasmus MC Cancer Institute, University Medical Center, Department of Hematology, Rotterdam, Netherlands, Erasmus University Rotterdam, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Amphia Hospital, Cancer Center Amsterdam,

Abstract

Preliminary antitumor activity of the combination of COM701 + BMS-986207 + nivolumab in patients with recurrent, metastatic MSS endometrial cancer.

Org: West Cancer Center & Research Institute, University of Chicago, Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Massachusetts General Hospital,

Abstract

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases.

Org: University of Chicago, UPMC Hillman Cancer Center, H. Lee Moffitt Cancer Center and Research Institute,

Abstract

LUNG-IST-127: A pilot phase II study of maintenance cabozantinib plus pembrolizumab for patients with metastatic squamous non-small cell lung cancer (sqNSCLC) with disease control following induction therapy.

Org: Department of Hematology Oncology University of Illinois of Chicago College of Medicine, University of Ilinois Chicago, Department of Surgery University of Illinois of Chicago College of Medicine, University of Illinois Chicago, Jesse Brown VAMC,

Abstract

Study EV-103: Neoadjuvant treatment with enfortumab vedotin monotherapy in cisplatin-ineligible patients (pts) with muscle invasive bladder cancer (MIBC): Updated results for Cohort H.

Org: Astellas Pharma Inc., Seagen, Inc.,

Abstract

Final results of pilot trial to evaluate anti-PD1 and 8 Gy in 1 fx for relapsed refractory multiple myeloma.

Org: Emory University, Atlanta, GA, USA, Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan,

Abstract

STELLAR-303: A phase 3 study of XL092 in combination with atezolizumab versus regorafenib in patients with previously treated metastatic colorectal cancer.

Org: David Geffen School of Medicine at UCLA, Jonsson Comprehensive Cancer Center, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Department of Medicine, Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Exelixis, Inc.,

Abstract

To test, or not to test, that is the question: A real-world analysis of PD-L1 expression testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).

Org: Merck & Co., Inc., Dana-Farber Cancer Institute,

Abstract

Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with early-stage, triple-negative breast cancer.

Org: University of Texas Southwestern Medical Center, UT Southwestern Medical Center,

Abstract

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.

Org: Dana-Farber Cancer Institute, University of Pennsylvania, The Cancer Institute Hospital of JFCR, Tokyo, Japan, University of California Comprehensive Cancer Center, University of North Carolina at Chapel Hill,

Abstract

Phase II basket trial evaluating the efficacy of pembrolizumab (PE) combined with vorinostat (VO) in patients (pts) with recurrent and/or metastatic squamous cell carcinoma (SCC).

Org: Curie Institute, Institut de Cancerologie de l'Ouest, Saint-Herblain, France, ICO Institut de Cancerologie de l'Ouest, Drug Development and Innovation Department, Center Georges-Francois Leclerc,

Abstract

Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).

Org: University of Pennsylvania, Stanford Cancer Center,

Abstract

A phase 2 trial of chemotherapy, pembrolizumab, and propranolol in patients with advanced esophageal/gastroesophageal junction adenocarcinoma (EGAC).

Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, Division of GI Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Roswell Park Cancer Institute,

Abstract

Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer.

Org: Roswell Park Comprehensive Cancer Center, Buffalo, IL, Nykode Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, Tampa General Hospital,

Abstract

Impact of neoadjuvant chemo-immunotherapy on surgical outcomes and time to radiation in triple negative breast cancer.

Org: Breast Service, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Memorial Sloan Kettering Cancer Center, New York, NY, Biostatistics Service,

Abstract

IMPORT-201 (IMP-MEL): A phase 1 first-in-human dose finding/randomized phase 2 study of a novel iNKT agonist IMM60 and pembrolizumab for advanced melanoma and metastatic non-small cell lung cancer (NSCLC).

Org: Oxford University Hospitals NHS Trust, Department of Surgery and Cancer, Imperial College, Portage Biotech, Oncology Clinical Trials Office, University of Oxford, Department of Oncology, University of Oxford,

Abstract

Combined pulsed radiotherapy (QUAD shot regimen) with immune checkpoint inhibition (ICI) to enhance immune response for LAHNSCC in patients considered ineligible for curative intent therapy.

Org: Grandview Cancer Center, Helen F. Graham Cancer Center and Research Institute, Newark, DE, Thomas Jefferson University Hospital, Christiana Care Health System, Med Onc / Hem Consultants,

Abstract

STAR-121: A phase 3, randomized study of domvanalimab (DOM) and zimberelimab (ZIM) in combination with chemotherapy vs pembrolizumab (pembro) and chemotherapy in patients with untreated metastatic non-small cell lung cancer (mNSCLC) with no actionable gene alterations.

Org: Moffitt Cancer Center, Samsung Medical Center, Sarah Cannon Research Institute/Tennessee Oncology, Gilead Sciences, Inc., Arcus Biosciences,

Abstract

The controversial abscopal effect: A single-center experience about the combination of stereotactic radiotherapy with pembrolizumab in patients with metastatic dMMR/MSI-H colorectal cancer.

Org: IRCCS Ospedale Policlinico San Martino, Sant’Orsola Malpighi Hospital, University of Bologna,

Abstract

A phase 1 first-in-human clinical trial of HMBD-002, an IgG4 monoclonal antibody targeting VISTA, in advanced solid tumors.

Org: Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, University of Texas Southwestern Medical Center, Dallas, TX, Stanford Cancer Center GI Surgical Oncology, Stanford, CA, Cedars-Sinai Cancer Institute, Los Angeles, CA, Cedars-Sinai Medical Center, Los Angeles, CA,

Abstract

Immunotherapy for localized MSI-H colorectal cancer: Characterizing endoscopic and imaging response.

Org: Baylor College of Medicine, University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China,

Abstract

Efficacy and safety study of neoadjuvant efineptakin alfa (NT-I7) and pembrolizumab in recurrent glioblastoma.

Org: Mayo Clinic, Alliance Statistics and Data Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Department of Neurology, Brigham and Woman’s Hospital, Harvard Medical School, Boston, MA, Mayo Clinic Cancer Center,

Abstract

A phase 1 study of TPST-1495 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.

Org: University of Okahoma Health Sciences Center, Carolina BioOncology Institute, Sarah Cannon Research Institute/Tennessee Oncology, University of Michigan, START Midwest, Grand Rapids, MI,

Abstract

Phase 1 study of WNT pathway Porcupine inhibitor CGX1321 and phase 1b study of CGX1321 + pembrolizumab (pembro) in patients (pts) with advanced gastrointestinal (GI) tumors.

Org: Dana-Farber Cancer Institute, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, Georgetown University Hospital, Washington, DC, Lombardi Comprehensive Cancer Center, START San Antonio,

Abstract

Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.

Org: University of Calgary, Texas Oncology PA, Ipsen, Ontada, McMaster University and Juravinski Cancer Centre,

Abstract

Immunotherapy for localized dMMR/MSI tumors: First interim analysis of the IMHOTEP trial.

Org: Centre Leon Berard, Lyon I University, Hôpital Européen Georges Pompidou, Sorbonne University and Saint-Antoine Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,

Abstract

Melanomas lacking HLA class I expression and response to checkpoint inhibitor.

Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY,

Abstract

Phase 2 trial of epidermal growth factor (EGF) vaccine CIMAvax in combination with pembrolizumab in first line and maintenance setting in advanced non–small cell lung cancer patients.

Org: Roswell Park Comprehensive Cancer Center, Roswell Park Comprehensive Cancer Institute, University Hospitals, Case Comprehensive Cancer Center, Department of Hematology/Oncology, IU Simon Comprehensive Cancer, Catholic Health Systems,

Abstract

State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.

Org: Clinical Care Options, LLC, Reston, VA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA, Taussig Cancer Institute, Cleveland Clinic Taussig Cancer Instititute,

Abstract

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

Org: Yonsei Cancer Center, Yonsei University Health System, Maria Sklodowska-Curie National Research Institute of Oncology, James Lind Cancer Research Center, Temuco, Chile, Harbin Medical University Cancer Hospital, Asan Medical Center,

Abstract

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

Org: Washington University School of Medicine in St Louis, Natco Pharma, NATCO Pharma Limited,

Abstract

A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors.

Org: City of Hope Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, The Sarah Cannon Research Institute, Knight Cancer Institute, Cedars-Sinai Cancer Center,

Abstract

Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in head and neck cancer (HNSCC) patients.

Org: H. Lee Moffitt Cancer Center and Research Institute, Duke Medical Center, Moffitt Cancer Center, Advent Health, University of South Florida Morsani College of Medicine,

Abstract

Randomized phase II trial of olaparib + pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.

Org: City of Hope National Medical Center, Fred Hutchiinson Cancer Research Center, SWOG Statistics and Data Management Center, Seattle, WA, Johns Hopkins University School of Medicine, University of Pennsylvania,

Abstract

Ultra-sensitive, tumor-informed ctDNA profiling in patients with gastroesophageal cancer and treated with pembrolizumab and longitudinal ctDNA kinetics.

Org: Duke University Medical Center, Personalis, Inc., University of North Carolina at Chapel Hill, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

Phase 1/2 study of mRNA-4359 administered alone and in combination with immune checkpoint blockade in adult participants with advanced solid tumors.

Org: Carolina BioOncology Institute, Massachusetts General Hospital, Hackensack Meridian Health, Moderna Therapeutics, Department of Thoracic Medical Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,

Abstract

Differences in real-world pembrolizumab dosing patterns (every 3 weeks versus every 6 weeks) across a large cancer center network.

Org: University of Pittsburgh School of Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, UPMC Hillman Cancer Center Biostatistics Facility,

Abstract

Association of neutrophil-lymphocyte ratio (NLR) with clinical outcomes in patients (pts) with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with combination of cetuximab and nivolumab (C+N).

Org: Moffitt Cancer Center, The Ohio State University - James Cancer Hospital and Solove Research Institute, Emory University School of Medicine, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida Morsani College of Medicine,

Abstract

Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.

Org: Adana Baskent Üniversitesi, Adelaide and Meath Hospital, University College Dublin, Instituto Valenciano de Oncología, Ivanovo Regional Oncology Dispensary,

Abstract

Evaluating generalizability of practice-changing randomized clinical trials in non-small cell lung cancer using machine learning-based in-silico trials.

Org: Chinle Comprehensive Health Care Facility, Perelman School of Medicine, University of Pennsylvania, Flatiron Health, San Francisco, CA,

Abstract

A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer.

Org: University of Texas Southwestern Medical Center, Memorial Sloan Kettering Cancer Center, CLION-CAM Group, Cedars-Sinai Medical Center, Cedars-Sinai Cancer,

Abstract

A phase II study of lenvatinib plus pembrolizumab in patients with progressive, recurrent/metastatic adenoid cystic carcinoma.

Org: MSKCC, Memorial Sloan Kettering Cancer Center,

Abstract

Development of a novel immune-related toxicity grading system for predicting outcomes in patients with solid tumours treated with immune checkpoint inhibitors (ICI).

Org: King's College London, Guy's and St. Thomas' NHS Foundation Trust, Guy's and St. Thomas' Hospital, Guys' and St. Thomas' NHS Foundation Trust,

Abstract

Long-term outcomes of pembrolizumab (pembro) in combination with gemcitabine (gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIUC): A multicenter phase 2 trial.

Org: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, University of Chicago Comprehensive Cancer Center, Chicago, IL, University of Michigan Rogel Comprehensive Cancer Center, Memorial Sloan Kettering Cancer Center, Lineberger Comprehensive Cancer Center,

Abstract

Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.

Org: University of Rochester Cancer Center & Wilmot Cancer Institute, Vaccinex, Inc., University of North Carolina at Chapel Hill,

Abstract

Consensus molecular subtyping of colorectal cancer to demonstrate cetuximab benefit in right-sided CMS2 tumors, and pembrolizumab benefit in MSS CMS1 tumors.

Org: Caris Life Sciences, Irving, TX, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical School,

Abstract

Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial.

Org: University of Texas Southwestern Medical Center, Clion - CAM Group, Cedars-Sinai Medical Center, Cancer Care Assoc-TMPN, Cancer Care Associates of York,

Abstract

Pembrolizumab vs placebo for early-stage non‒small-cell lung cancer after resection and adjuvant therapy: Subgroup analysis of patients who received adjuvant chemotherapy in the phase 3 PEARLS/KEYNOTE-091 study.

Org: North Estonia Medical Centre Foundation, The Catholic University of Korea, Hiroshima University Hospital, Wielkopolskie Centrum Pulmonologii i Torakochirurgii im. Eugenii i Janusza Zeylandów, Medical Oncology 2, Istituto Oncologico Veneto IOV IRCCS, Padova, Italy,

Abstract

Phase II study of telomelysin (OBP-301) in combination with pembrolizumab in gastroesophageal (GEA) adenocarcinoma.

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, University of Pennsylvania, Weill Cornell Medical College University, University of Pennsylvania Health System,

Abstract

A phase I trial of sequential dosing of sonidegib and pembrolizumab in advanced solid tumors (aST) and non–small-cell lung cancer (NSCLC).

Org: Mayo Clinic, Division of Biomedical Statistics and Informatics, Mayo Clinic Florida, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Department of Quantitative Science Research,

Abstract

Impact of smoking status (SS) on the clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with first line (1L) immuno-oncology (IO)-combination regimens: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).

Org: Huntsman Cancer Institute at the University of Utah, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Harvard Medical School, BC Cancer Agency Vancouver Island Centre, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada,

Abstract

A phase 1a dose-escalation study of PY159, a monoclonal antibody targeting TREM1 (triggering receptor expressed on myeloid cells 1).

Org: Barbara Ann Karmanos Cancer Institute, Detroit, MI, Clinical Research at South Texas Accelerated Research Therapeutics (START), San Antonio, TX, Mary Crowley Cancer Research Center, Dallas, TX, Division of Hematology & Medical Oncology, Oregon Health and Science University, Portland, OR, University of Colorado - Anschutz Medical Campus, Aurora, CO,

Abstract

REFINE-Lung: A multicentre phase III study to determine the optimal frequency of pembrolizumab in non-small cell lung cancer utilising a novel multi-arm design.

Org: Imperial College London, MRC Clinical Trials Unit UCL, Christie Hospital NHS Foundation Trust and the University of Manchester, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, University of Liverpool,

Abstract

Real-world comparison between 6 weeks versus 3 weeks adjuvant pembrolizumab in high-risk stage IIB-IIID cutaneous malignant melanoma: Experience from an academic cancer center.

Org: The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center,

Abstract

Preliminary translational immune and stromal correlates in a randomized phase II trial of pembrolizumab with or without defactinib for resectable pancreatic ductal adenocarcinoma (PDAC).

Org: Cedars-Sinai Medical Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Johns Hopkins University Bloomberg School of Public Health, Verastem, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA,

Abstract

Head-to-head effectiveness and safety of pembrolizumab plus axitinib vs. nivolumab plus ipilimumab in metastatic renal cell carcinoma in the United States.

Org: Faculty of Biology, Technion-Israel Institute of Technology, Carelon Digital Platforms,

Abstract

Minimal residual disease by circulating tumor DNA as a biomarker of recurrence free survival in resected high-risk melanoma patients treated with mRNA-4157/V940, a personalized cancer vaccine, and pembrolizumab.

Org: Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, Earle A. Chiles Research Institute, Portland, OR, California Pacific Medical Center Research Institute, San Francisco, CA, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, The Angeles Clinic and Research Institute, Los Angeles, CA,

Abstract

IMRT followed by pembrolizumab in the adjuvant setting in anaplastic cancer of the thyroid (IMPAACT): Phase II trial adjuvant pembrolizumab after IMRT in ATC.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, Department of Head and Neck Surgery & Communication Sciences, Duke University School of Medicine, Durham, NC, University of Texas at MD Anderson Cancer Center,

Abstract

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

Org: IRCCS Ospedale Pediatrico Bambino Gesu, University College London Hospitals NHS Foundation Trust, Hospital Universitari Vall d Hebron, Regina Margherita Childrens Hospital and University of Turin, Turin, Italy, Princess Máxima Centrum,

Abstract

A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study.

Org: Department of Hematology and Clinical Oncology, Shinshu University School of Medicine, Matsumoto-Shi, Japan, Department of Pulmonary Medicine and Clinical Immunology, Dokkyo Medical University School of Medicine, Mibu, Japan, Department of Thoracic Oncology, Kansai Medical University Hospital, Osaka, Japan, Department of Biostatistics and Bioinformatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Japan,

Abstract

Neoadjuvant pembrolizumab, GX-188E, and GX-I7 in patients with human papillomavirus-16- and/or 18-positive head and neck squamous cell carcinoma: Single-arm, phase 2 trial with single cell transcriptomic analysis and artificial intelligence-powered spatial analysis.

Org: Genome Insight Inc., Heavy Ion Research Institute, Korea Advanced Institute of Science and Technology, Lunit Inc.,

Abstract

Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: A multicenter open-label phase 1/2a trial.

Org: Yonsei University College of Medicine, Severance Hospital, SMT Bio, SMT bio Co.Ltd,

Abstract

Tazemetostat, a selective EZH2 inhibitor, with pembrolizumab as treatment of anti-PD-1 resistant head and neck squamous-cell carcinoma (HNSCC): A phase 1-2 trial.

Org: Washington University School of Medicine in St Louis, Washington University Siteman Cancer Center, St. Louis, MO,

Abstract

First-in-class oral innate immune activator BXCL701 combined with pembrolizumab, in patients with metastatic castration-resistant prostate cancer (mCRPC) of small cell neuroendocrine (SCNC) variant: Randomized phase 2b trial.

Org: Moffitt Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Northwell Health, New Hyde Park, NY, Center for Cancer Care at White Plains Hospital, Yale School of Medicine,

Abstract

A phase 1B dose escalation study of ETC-159 in combination with pembrolizumab in advanced or metastatic solid tumours.

Org: National University Cancer Institute, Singapore, Yong Loo Lin School of Medicine, National University of Singapore, National Cancer Centre Singapore, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, UCHealth Cancer Care-Anschutz Medical Campus-University of Colorado Cancer Center, Aurora, CO,

Abstract

Pembrolizumab, radiotherapy, and chemotherapy in neoadjuvant treatment of malignant esophago-gastric diseases (PROCEED): Assessment of pathologic response and toxicity in a prospective, phase II single-arm trial.

Org: Duke Cancer Institute, Duke University Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,

Abstract

A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.

Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Brigham and Women’s Hospital, Harvard Medical School, Department of Urology, Jinling Hospital, Clinical School of Medical College, Nanjing University, Nanjing, China, University of California Davis Comprehensive Cancer Center,

Abstract

Immune infiltrates in metastatic uveal melanoma liver metastases and associations with clinical outcomes.

Org: Mayo Clinic, Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics,

Abstract

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

Org: Lungen Clinic Grosshansdorf, Airway Research Center North (ARCN), German Center of Lung Research (DZL), Grosshansdorf, Servicio de Oncología Médica, Hospital Universitario de Jaén, European Institute of Oncology,

Abstract

Phase II trial of consolidation pembrolizumab (pembro) after proton reirradiation (re-RT) for thoracic recurrences of non-small cell lung cancer (NSCLC).

Org: University of Pennsylvania, Philadelphia, PA, PainReform, CVS Health, Perelman School of Medicine,

Abstract

ARC-10: A phase 3 study to evaluate zimberelimab + domvanalimab versus pembrolizumab in front-line, PD-L1-high, locally advanced or metastatic non–small-cell lung cancer.

Org: Arcus Biosciences, Gilead Sciences, Inc.,

Abstract

Long-term efficacy and safety of pembrolizumab with R-CHOP as first-line therapy for DLBCL.

Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Centre, Seagen, Inc.,

Abstract

Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials.

Org: Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Cliniques Universitaires Saint-Luc (UCLouvain), Brussels, Belgium, Aichi Medical University, Nagakute, Japan, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Tokyo Medical and Dental University Hospital, Tokyo, Japan,

Abstract

Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).

Org: Biomedical Statistics Center, Samsung Medical Center, Seoul, South Korea, Department of Biomedical Science, CHA university, Seongnam, South Korea, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Center for Gynecologic Cancer, National Cancer Center, Ilsandong-Gu, Goyang-Si, South Korea, Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore,

Abstract

The genomic, transcriptomic, and immunological landscape of SGLT2 in lung cancer.

Org: University of Miami/Jackson Memorial Hospital, University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Caris Life Sciences, Irving, TX, Jackson Memorial Hospital/ University of Miami, Lombardi Comprehensive Cancer Center, Georgetown University,

Abstract

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

Org: Iovance Biotherapeutics, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research,

Abstract

Uncovering mechanisms of response of pembrolizumab and lenvatinib for the treatment of platinum-resistant high grade serous ovarian cancer.

Org: University of Texas MD Anderson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Houston, University of Texas - M. D. Anderson Cancer Center,

Abstract

Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC): Final results.

Org: Moffitt Cancer Center, Duke Cancer Institute,

Abstract

A phase III randomized trial of eribulin (E) with or without gemcitabine vs standard of care (SOC) for metastatic urothelial carcinoma (UC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937.

Org: SWOG Statistics and Data Management Center, Seattle, WA, University of California Davis Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, SWOG Cancer Research Network, Baylor College of Medicine,

Abstract

First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.

Org: Memorial Sloan Kettering Cancer Center, Macquarie University, Volga District Medical Center, Federal Medical-Biological Agency, Medical Oncology Group,

Abstract

Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.

Org: H. Lee Moffitt Cancer Center and Research Institute, Banner MD Anderson Cancer Center, Moffitt Cancer Center, Johns Hopkins Medicine, Nanobiotix,

Abstract

Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.

Org: Georgetown University Medical School, Genentech, Genesis Research Group, Genentech Inc., West Cancer Center & Research Institute,

Abstract

Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC).

Org: Memorial Sloan Kettering Cancer Center, Resolution Bioscience, Agilent,

Abstract

Evaluation of ICI sensitivity for pembrolizumab in combination with anti-platelet therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC).

Org: The Pelotonia Institute for Immuno-Oncology, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Columbus, OH, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC,

Abstract

Real-world outcomes of first-line immune checkpoint inhibitors with or without chemotherapy in KRAS G12C altered NSCLC according to PD-L1 status.

Org: Mirati Therapeutics, Tempus Labs, Inc., Northwestern University-Feinberg School of Medicine,

Abstract

Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected stage II/III melanoma.

Org: Rush University Medical Center, Natera, Inc.,

Abstract

Efficacy of sacituzumab govitecan (SG) in locally advanced (LA) or metastatic urothelial cancer (mUC) by trophoblast cell surface antigen 2 (Trop-2) expression.

Org: Institut de Cancérologie Gustave Roussy, Villejuif, France, France, Perlmutter Cancer Center at NYU Langone Health Medical Center, New York, NY,

Abstract

Results from a first-in-human phase 1B study of a complement factor H inhibitor (GT103) in patients with non-small cell lung cancer (NSCLC).

Org: Duke Cancer Institute, Duke University Medical Center, Barbara Ann Karmanos Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute, AdventHealth Cancer Institute, Orlando, FL,

Abstract

PLUME: A single-arm phase II trial evaluating the combination of pembrolizumab and lenvatinib in metastatic uveal melanoma (mUM) patients (pts) previously treated or not with tebentafusp.

Org: Institut Curie, Saint Cloud, France, Curie Institute, Department of Drug Development and Innovation (D3i),

Abstract

OMNIA-1: A phase I/II study, an IL-2R-βγ targeted antibody-IL-2 fusion protein, as monotherapy or in combination with anti‑PD-1 or anti-CTLA-4 antibodies, in patients with advanced melanoma.

Org: Istituto Nazionale Tumori IRCCS Fondazione Pascale, Hospital Universitario 12 de Octubre, Charite-Universitaetsmedizin, Berlin, Germany, Chugai Pharmaceutical, Anaveon,

Abstract

Safety, efficacy and biomarker data in non-small cell lung cancer patients treated with the anti-IL1RAP antibody nadunolimab in combination with platinum doublet.

Org: Hospital Universitario 12 de Octubre, Madrid, Spain, Centre Hospitalier Universitaire de Liège, Liège, Belgium, Department of Pulmonology Medical Academy Lithuania University of Health Sciences, Kaunas, Lithuania, National Cancer Institute, Vilnius, Lithuania, Riga East Clinical University Hospital, Riga, Latvia,

Abstract

Evaluating the efficacy and safety of pembrolizumab monotherapy or in combination with standard chemotherapy in the first-line treatment of locally recurrent head and neck squamous cell carcinoma in different TP53 and PI3K statuses.

Org: Beijing Tongren Hospital, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, China,

Abstract

Efficacy-effectiveness gap with immune checkpoint inhibitors in solid cancers: A population based cohort study.

Org: University of Manitoba, CancerCare Manitoba,

Abstract

Updated results from an ongoing phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via IT injection as monotherapy or combined with pembrolizumab in advanced solid tumors.

Org: Banner MD Anderson Cancer Center, Massachusetts General Hospital, Southern Oncology Clinical Research Unit Pty Ltd., Alfred Hospital and Monash University, Mary Crowley Cancer Research Center,

Abstract

PEMBROCABOSARC: Combination of pembrolizumab and cabozantinib in patients with advanced sarcomas.

Org: Institut Bergonie, Institut Bergonié, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Institut Paoli Calmettes, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,

Abstract

TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.

Org: Gustave-Roussy Cancer Campus, Institut Claudius Regaud, IUCT-Oncopole Toulouse, Institut Paoli Calmettes, Biostatistic Unit, IRCCS Humanitas Research Hospital, Rozzano (Milano), Italy,

Abstract

A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.

Org: A.C. Camargo Cancer Center, Hospital de Amor de Barretos, Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto, Liga Norte Riograndense Contra o Câncer, Centro Regional Integrado de Oncologia (CRIO),

Abstract

Real-world evidence to inform clinical insights on tissue-agnostic approvals of therapies.

Org: Caris Life Sciences, Irving, TX, National Cancer Center Hospital East, Kashiwa, Japan,

Abstract

A phase II study of talimogene laherparepvec (T-VEC) and pembrolizumab in patients with advanced sarcoma: Results of expansion cohorts.

Org: Memorial Sloan Kettering Cancer Center, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sarcoma Medical Oncology Service,

Abstract

Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.

Org: Virginia Cancer Specialists, US Oncology Network, Mirati Therapeutics, Ontada,

Abstract

Safety of checkpoint inhibitors in older patients with genitourinary cancers.

Org: University of Florida/UF Health Cancer Center, University of Florida Department of Health Outcomes and Biomedical Informatics,

Abstract

Final results from a phase II trial of CIMAvax-EGF and nivolumab as second-line (2L) therapy after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Org: Roswell Park Comprehensive Cancer Center, Buffalo, NY, IU Simon Comprehensive Cancer Center, Indianapolis, IN, Innovative Immunotherapy Alliance,

Abstract

ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Org: Duke Cancer Institute, Duke University Medical Center, Sarcoma Oncology Center, Department of Sarcoma, H. Lee Moffitt Cancer Center and Research Institute, Royal Marsden Hospital and Institute of Cancer Research,

Abstract

Incidence of venous thromboembolism with immune checkpoint inhibitors in a community setting: A single-center retrospective study.

Org: Saint Vincent Hospital Cancer Center Green Bay, Saint Vincent Cancer and Wellness Center,

Abstract

Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: Interim results of a phase 2 multi-center trial.

Org: Rutgers Cancer Institue of New Jersey, Winship Cancer Institute, Emory University School of Medicine, Division of Surgical Oncology, Department of Surgery, The Ohio State University, Department of Surgery, Brigham and Women's Hospital, Boston, MA, Emory University, Atlanta, GA, USA,

Abstract

Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.

Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,

Abstract

Delayed immune toxicities in patients with breast cancer receiving immune checkpoint inhibitors.

Org: University of California San Francisco, University of California Irvine, University of Minnesota Masonic Cancer Center, Minneapolis, MN, University of California Comprehensive Cancer Center,

Abstract

Immune checkpoint inhibition in locally advanced rectal adenocarcinoma at Mayo Clinic.

Org: Mayo Clinic, Jacksonville, FL,

Abstract

Evaluation of immunotherapy response score (IRS) for predicting pembrolizumab (pembro) clinical benefit in patients (pts) with advanced solid tumors.

Org: Kaiser Permanente Oakland Medical Center, Vallejo, CA, CanSino Biologics, Oakland, CA, Strata Oncology,

Abstract

Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06).

Org: Soonchunhyang University Bucheon Hospital, Pusan National University Yangsan Hospital, Ulsan University Hospital, College of Medicine, Chungbuk National University, Seoul St. Mary's Hospital,

Abstract

Immunotherapy-related toxicities: A retrospective analysis of barriers to prompt detection and initiation of treatment in renal cell carcinoma.

Org: TCU School of Medicine, UTSW Harold C Simmons Comprehensive Cancer Center,

Abstract

Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer.

Org: UPR "Chronotherapy, Cancer and Transplantation", Medical School, Paris-Saclay University, Villejuif, France, Medical Oncology unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Medical Oncology Unit, Hôpital Avicenne, APHP, Bobigny, France, Paul Brousse hospital, Assistance Publique-Hopitaux de Paris, Villejuif, France, Digestive and Medical Oncology Unit, Paris-Saclay University, Paul Brousse Hospital, Assistance Publique-Hopitaux de Paris, Villejuif, France,

Abstract

The influence of sex on the impact of age and frailty on acute care use among older adults receiving immune checkpoint inhibitor (ICI) treatment: A population-based study.

Org: Princess Margaret Cancer Centre, ICES, Ontario Health (Cancer Care Ontario), Princess Margaret - University Health Network, University Health Network,

Abstract

Efficacy and safety of first-line immunotherapy for advanced gastric or gastroesophageal cancer: System review network meta-analysis.

Org: Tianjin Medical University General Hospital, Tianjin, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,

Abstract

The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma.

Org: Memorial Sloan Kettering Cancer Center, Merck & Co, Inc., Linnaeus Therapeutics, Massachusetts General Hospital Cancer Center, Surgical Oncology, Boston, MA, Yale Cancer Center, Yale School of Medicine, New Haven, CT,

Abstract

A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer.

Org: Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Henan Cancer Hospital, Zhengzhou, China, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital,

Abstract

Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.

Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, UT Southwestern Medical Center, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, MSMC,

Abstract

Real-world experience of checkpoint inhibitors across India: CRSF 2020-01.

Org: Max Super Speciality Hospital, Aster Mims Calicut, Malabar Cancer Centre, Regency Hospital, Bombay Hospital,

Abstract

A phase 3 trial comparing fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) to pembrolizumab in patients with completely resected high-risk melanoma.

Org: University of Tennessee Medical Center at Knoxville, Orlando Health Cancer Institute, Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, St. John's Cancer Institute, Santa Monica, CA,

Abstract

Different efficacy of pembrolizumab in overall survival between Asians and non-Asians with advanced cancers: A systematic review and meta-regression analysis.

Org: National Taiwan University Hospital Yunlin Branch, National Taiwan University Cancer Center/Hospital,

Abstract

A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).

Org: Ascentage Pharma Group, Ascentage Pharma (Suzhou) Co., Ltd., State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital,

Abstract

Association between severe adverse event management and overall survival in patients treated with immune checkpoint inhibitor with advanced non–small-cell lung cancer.

Org: Beaumont RCSI Cancer Center, Vanderbilt University Medical Center, ConcertAI, Bristol Myers Squibb, Bristol-Myers Squibb,

Abstract

A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).

Org: UPMC Hillman Cancer Center, University of Oklahoma Stephenson Cancer Center, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Cancer Center at Thomas Jefferson University,

Abstract

Factors associated with response to neoadjuvant chemotherapy and immune checkpoint inhibition in triple-negative breast cancer.

Org: City of Hope Comprehensive Cancer Center, Duarte, CA, Cedars-Sinai Cancer Center, Los Angeles Medical Center,

Abstract

Integrating the 31-gene expression profile test into clinical decision-making to guide risk-aligned care decisions for patients with stage I-III cutaneous melanoma: NCI-SEER Analysis.

Org: Desert Surgical Oncology, National Cancer Institute, Vilnius, Lithuania, National Institutes of Health All of Us Research Program, Castle Biosciences, Castle Biosciences, Inc.,

Abstract

Reveal irAE by analysis of 197,921 claim-based prescriptions.

Org: AESOP Technology Inc.,

Abstract

Carboplatin beyond 4 cycles during therapy with carboplatin, pemetrexed, and pembrolizumab for advanced non-small cell lung cancer (NSCLC).

Org: Morsani College of Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, Moffitt Cancer Center,

Abstract

Predictors of response in advanced colorectal cancer (CRC) patients treated with immune-checkpoint inhibitors (ICI).

Org: The Ohio State University College of Medicine, Ohio State University Wexner Medical Center, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, Wexner Medical Center and The James Cancer Hospital, Ohio State University,

Abstract

Phase II study combining an anti-core 1 O-glycans targeting humanized monoclonal antibody NEO-201 with pembrolizumab in adults with chemo-resistant solid tumors.

Org: Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD, Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, NCI/CBIIT, Bethesda, MD, Precision Biologics, Inc., Bethesda, MD, Precision Biologics, Bethesda, MD,

Abstract

The association between body mass index and immune checkpoint inhibitors outcomes in melanoma: Results from real-world data.

Org: MetroHealth Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University, Seidman Cancer Center,

Abstract

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Org: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Department of Cutaneous Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, Moffitt Cancer Center and Research Institute, Tampa, FL, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, The Univ of Utah, Salt Lake City, UT,

Abstract

Integrated survival analysis.

Org: Cedars-Sinai Comprehensive Cancer Center, The Angeles Clinic and Research Institute, Marymount University Hospice,

Abstract

ARTISTRY-7: A phase 3, multicenter study of nemvaleukin alfa in combination with pembrolizumab versus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer (GOG-3063; ENGOT-OV68).

Org: College of Medicine, University of Cincinnati, Wexner Medical Center and The James Cancer Hospital, Ohio State University, Women's Cancer Care Associates, Arizona Oncology Associates, Texas Oncology - Fort Worth Cancer Center,

Abstract

Cancer therapy-associated thrombosis: A patient- reported outcomes (PROs) analysis.

Org: Care Across,

Abstract

Evaluation of immune related adverse events following extended interval dosing of immune checkpoint inhibitors.

Org: Gundersen Health System, La Crosse, WI, Gundersen Clinic Ltd,

Abstract

Real-world treatment sequencing and outcomes for patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy: Results from the CARINA study.

Org: Mount Vernon Cancer Center, Northwood, United Kingdom, Christie NHS Foundation Trust, Manchester, United Kingdom, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, Royal Preston Hospital,

Abstract

Multicenter pharmacokinetic study of pembrolizumab for non-small cell lung cancer in adults aged older than 75 years.

Org: Kansai Medical University Hospital, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, National Cancer Center Hospital East, Kashiwa, Japan, Kitasato Daigaku Igakubu, Sagamihara-Shi Minami-Ku, Japan,

Abstract

Org: Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany, Cleveland Clinic Taussig Cancer Instititute, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer.

Org: NSABP/NRG Oncology and the UPMC Hillman Cancer Center, University of Texas MD Anderson Cancer Center, SWOG, Hospital Clinic of Barcelona, Perlmutter Cancer Center, New York University Langone Health,

Abstract

Augmented curation of disease diagnoses and medications for patients with hepatocellular carcinoma.

Org: nference, nference Labs,

Abstract

A first-in-human phase I trial of a novel peptide vaccine LabVax 3(22)-23 and adjuvant GM-CSF sargramostim in patients with refractory labyrinthin-expressing adenocarcinomas.

Org: University of California Davis Comprehensive Cancer Center, Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, University of California Davis, Sacramento, CA, UC Davis Comprehensive Cancer Center, Sacramento, CA, LabyRx Immuno-Oncology,

Abstract

Retrospective analysis of digital biomarker predictability of immune checkpoint inhibitor therapy outcomes in patients with NSCLC.

Org: Astellas Pharma, University of Michigan, Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Emory University, Atlanta, GA, USA,

Abstract

TIGIT expression and outcomes in pembrolizumab treated patients with NSCLC.

Org: OmniSeq Inc. (Labcorp), Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Phase 1/2 dose escalation and dose expansion study of TransCon IL-2 β/γ alone or in combination with pembrolizumab: Initial results from dose escalation.

Org: The Christ Hospital Health Network, Carolina BioOncology Institute, Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, UPMC Hillman Cancer Center, Tasman Oncology Research,

Abstract

Evolution of breast cancer management in the Dominican Republic in the 21st century.

Org: FUNDEONCAP, IOHP, Dominican Society of Oncology,

Abstract

Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.

Org: Geneos Therapeutics, Plymouth Meeting, PA, Personalis, Inc., Menlo Park, CA, University of Auckland,

Abstract

Influence of follow-up time on outcome of children and adolescents with atypical Spitz tumor/Spitz melanoma (AST/SM): Results from the MACMEL registry.

Org: St Jude Childrens Research Hospital, St. Jude Children's Research Hospital, Department of Oncology, St. Jude Children's Research Hospital,

Abstract

Efficacy and safety of pembrolizumab versus sintilimab treatment in patients with advanced squamous lung cancer: A real-world study in China.

Org: School of Medicine, Nankai University, Tianjin, China, Department of medical oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, School of Medicine, Nankai University, Beijing, China, Department of Oncology, the First Medical Center, Chinese PLA General Hospital, Beijing, China, Department of Medical Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China,

Abstract

Implementation of the novel use of an objective scoring rubric to reduce utilization of inpatient non-formulary chemotherapy.

Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Mount Sinai Health System, Mount Sina Health System,

Abstract

Biliary intervention combined with lenvatinib+ PD-1 inhibitor of Klatskin tumor complicated with malignant obstructive jaundice.

Org: Sun Yat-sen University Cancer Center Gansu Hospital, Guangzhou, China,

Abstract

Novel machine learning algorithm to predict response to immunotherapy in patients with small cell and non-small cell lung cancer.

Org: GKT School of Medicine, King's College London, Curenetics Ltd, Imperial College London, School of Physics, Engineering & Computer Science,

Abstract

Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with pembrolizumab in early-stage, triple-negative breast cancer.

Org: Duke University Hospital, Duke Cancer Institute, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Health System,

Abstract

Replacement of anti-PD-1 drugs with prolgolimab during treatment, safety and efficacy.

Org: AV Medical Group, Saint-Petersburg, Russian Federation, LLC Oncological Research Center, NII of Oncology name after Petrov,

Abstract

A phase 2 study of modified chemotherapy plus pembrolizumab as perioperative therapy for stage II/IIIA esophageal squamous cell carcinoma.

Org: The First Medical Center of PLA General Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, General Hospital of Chinese PLA, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital,

Abstract

Retrospective analysis of NUT carcinoma: The Northwestern experience.

Org: Northwestern Medicine Cancer Center Warrenville, Northwestern University-Feinberg School of Medicine, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Robert H. Lurie Comprehensive Cancer Center, Northwestern University,

Abstract

Obesity, dyslipidemia, and diabetes as determinants of response to immune checkpoint inhibitors in non-small cell lung cancer.

Org: Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Mount Auburn Hospital, Harvard Medical School, Lahey Hospital and Medical Center, Burlington, MA,

Abstract

Hemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: A pharmacovigilance study from FDA Database.

Org: Rochester General Hospital, Rochester, NY, Patan Academy of Health Sciences, Kathmandu, Nepal, Kathmandu, Nepal, University at Buffalo Jacobs School of Medicine and Biomedical Sciences,

Abstract

Measuring time toxicity of systemic therapies for advanced esophageal and gastric cancers.

Org: Oregon Health & Science University, Medical Oncology Group, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Knight Cancer Institute,

Abstract

Treatment patterns and clinical outcomes of newly diagnosed early-stage and locally advanced triple negative breast cancer (TNBC): A retrospective cohort analysis of national real-world data in England.

Org: Merck Sharp & Dohme, London Regional Cancer Center, Merck Sharpe & Dohme, Adelphi Real World, Bollington,

Abstract

Clinical and pathological description of patients with triple negative breast cancer undergoing neoadjuvant chemotherapy and pembrolizumab in a Brazilian cancer center.

Org: A.C. Camargo Cancer Center,

Abstract

Whole genome sequencing for more accurate TMB and mutational signatures in common cancers.

Org: Genome Insight Inc., Ajou University School of Medicine, Genome Insight, San Diego, CA, Seoul National University College of Medicine, Seoul National University Hospital,

Abstract

Meta-analysis of gastrointestinal adverse effects in patients with non-small cell lung cancer treated with a combination therapy of pembrolizumab and chemotherapy versus chemotherapy alone.

Org: Crozer Chester Medical Center, University of Pennsylvania, Crozer-Chester Medical Center,

Abstract

Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: A real-world observational chart review study.

Org: RTI Health Solutions, Pfizer Inc., London, United Kingdom,

Abstract

Real world data on immunotherapeutic outcomes in solid tumours.

Org: The Brunei Cancer Center, The Brunei Cancer Centre,

Abstract

Characterizing chromosome 3p/q genes as biomarkers of treatment response in squamous cell carcinoma of the lung and head and neck.

Org: UC San Diego Moores Cancer Center, Caris Life Sciences, Irving, TX, Lombardi Comprehensive Cancer Center, Hoag Memor Hosp, Hoag Family Cancer Institute and University of Southern California,

Abstract

Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.

Org: The University of Manchester and The Christie NHS Foundation Trust, University of Leicester and Leicester University Hospitals, University Hospitals Of Leicester NHS Trust, Northern Centre for Cancer Care, University of Newcastle, The Newcastle upon Tyne Hospitals NHS Foundation Trust,

Abstract

Use of tumor mutational burden as a predictive marker of response to immuno-oncology agents: Initial experience at an academic center in Venezuela.

Org: Centro Medico Docente La Trinidad, Caracas, Venezuela (Bolivarian Republic of), Beth Israel Deaconess Medical Center, Boston, MA, Advocate Aurora Health, Chicago, IL, Centro Medico Docente la Trinidad, Caracas, Miranda, Venezuela (Bolivarian Republic of),

Abstract

Profile of toxicities and quality of life in long-term survivors treated with immunotherapy: A prospective cross sectional trial.

Org: University of Brescia, ASST Spedali Civili - Brescia, University Hospital of Parma, University of Pisa, Pisa, Italy, ATC Innovation Lab,

Abstract

Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).

Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,

Abstract

Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.

Org: UC Irvine, University of California Irvine, UCI Health,

Abstract

Adrenal insufficiency in patients on immune checkpoint inhibitors: An All of Us Data study.

Org: Harlem Hospital Center, New York Oncology Hematology PC,

Abstract

Predicting non-small cell lung cancer response to immune checkpoint inhibitors with machine learning based on heterogeneous biomarkers.

Org: INRIA, Sophia Antipolis, Centre Antoine Lacassagne, Center hospitalier Princesse-Grace, Univ Rouen Normandie,

Abstract

Encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for unresectable locally advanced or metastatic BRAF V600-mutant melanoma: Results from STARBOARD safety lead-in (SLI).

Org: University Hospital Essen, Essen, Germany, University Hospital Zurich, Zurich, Switzerland, Gustave Roussy, Villejuif, France, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, Massachusetts General Hospital, Boston, MA, USA,

Abstract

Effect of multi-omics analysis on tumor ecosystem during neoadjuvant dose-limiting chemotherapy combination with sequential PD-1 blockade for patients with esophageal cancer.

Org: WiHealth Medical Laboratory, YuceBio Technology Co.,

Abstract

A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.

Org: Todua Clinic, Tbilisi, Georgia, High Technology Medical Centre, University Clinic, Tbilisi, Georgia, LTD High Technology Hospital Med Center, Batumi, Georgia, Consilium Medullla, Tbilisi, Georgia, LTD TIM Tbilisi Institute of Medicine, Tbilisi, Georgia,

Abstract

Immuno-embolization plus PD1 antibody in metastatic uveal melanoma.

Org: Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics, University of Missouri-Kansas City School of Medicine, Division of Vascular and Interventional Radiology,

Abstract

Atypical new metastatic sites after immunotherapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M H&NSCC).

Org: Inova Schar Cancer Institute, Inova Fairfax Hospital,

Abstract

Ustekinumab for the treatment of immune related cutaneous adverse events (ircAEs).

Org: Memorial Sloan Kettering Cancer Center,

Abstract

A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC.

Org: Centre for Cancer Biomarkers CCBIO, University of Bergen, Dept. of Urology, Haukeland University Hospital, Dept. of Pathology,

Abstract

Incidence and outcomes of immune-related adverse events after immune checkpoint inhibitors in patients with Hodgkin lymphoma.

Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, MetroHealth Medical Center, Case Western Reserve University School of Medicine, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Department of Hematology and Oncology, University Hospital Mannheim, Heidelberg University,

Abstract

Efficacy of checkpoint inhibitors in hospitalized patients with cancer.

Org: Rutgers Health Community Medical Center, Monmouth Medical Center, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,

Abstract

RNA sequencing as a confirmatory assay and its impact on patient care in multiple cancer types.

Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, BostonGene, Corp., University of Texas MD Anderson Cancer Center,

Abstract

Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.

Org: US Biotest,

Abstract

Utility of next generation sequencing (NGS) in advanced malignancies in a community hospital in an underserved area: A game changer?

Org: Mercy Catholic Medical Center, Lansdowne, PA, Darby, PA, PainReform,

Abstract

The smart options of induction therapy for locally advanced betel-nuts related HNSCC in Taiwan.

Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan Bio Therapeutics, Yun-lin Branch,

Abstract

Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).

Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital & Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,

Abstract

Tumour mutational burden as a predictive and prognostic biomarker in locally advanced and recurrent/metastatic adenoid cystic carcinoma.

Org: The Christie Hospital NHS Foundation Trust, Manchester Cancer Research Centre, The Christie NHS Foundation Trust, University of Manchester, Manchester, United Kingdom, The Christie NHS Foundation Trust, The University of Manchester and The Christie NHS Foundation Trust, Manchester University NHS Foundation Trust,

Abstract

Immune therapy related adverse events in metastatic non-small cell lung carcinoma patients at a rural academic center.

Org: Brody School of Medicine at East Carolina University, ECU Health,

Abstract

Low dose anti-PD(L)-1: A potentially effective alternative for greater accessibility in solid malignancies.

Org: Hospital de Base São José do Rio Preto, São José Do Rio Preto, Brazil, Hospital de Base de São José do Rio Preto, São José Do Rio Preto, Brazil, FAMERP, São José Do Rio Preto, Brazil, Hospital De Base Sao Jose Do Rio Preto, São José Do Rio Preto, Brazil, Hospital de Base de São José do Rio Preto, São José Do Rio Preto, ON, Brazil,

Abstract

Pathologic complete response (pCR) to neoadjuvant treatment (NAT) with carboplatin, nab-paclitaxel and anthracycline in early and locally advanced triple-negative breast cancer (TNBC).

Org: Medical Oncology Department, University Hospital Virgen del Rocío, Sevilla, Spain, Medical Oncology Department, University Hospital Puerto Real, Cádiz, Spain, Medical Oncology Department, University Hospital Virgen Macarena, Sevilla, Spain, University Hospital Virgen del Rocío, Sevilla, Spain, Hospital Virgen del Rocio de Sevilla. GEICAM Spanish Breast Cancer Group, Seville, Spain,

Abstract

Anti-drug antibodies related to CTLA-4, PD-1, or PD-L1 inhibitors across tumour types: A systematic review.

Org: Imperial College, University Medical Center Mainz, Mtech Access, Eisai, UCLA Medical Center,

Abstract

Efficacy comparison of anthracycline and taxane when added to immune checkpoint inhibitor in neoadjuvant chemotherapy of triple negative breast cancer: Clinical evidence from size-reduction measurement by ultrasound.

Org: Chang Gung Memorial Hospital at Taipei, Chang Gung University Medical College, Chang Gung Memorial Hospital, Department of General Surgery, Chang Gung Memorial Hospital at Tao-Yuan, Tao-Yuan, Taiwan, Department of Hematology-Oncology, Mayo Clinic Florida, Jacksonville, FL,

Abstract

Retrospective analysis of the multikinase inhibitor (MKI) pazopanib in differentiated thyroid carcinoma (DTC) in the beyond-first-line setting.

Org: Mayo Clinic, University of Missouri–Kansas City, Mayo Clinic Florida,

Abstract

A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.

Org: University of Texas Health Science Ctr, San Antonio, TX, The University of Arizona Cancer Center, Tucson, AZ, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Penn State Hershey Medical Center Cancer Institute, Hershey, PA, Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Nashville, TN,

Abstract

How comparable are outcomes for approved PD-1/PD-L1 checkpoint inhibitors (CPI)? A model-informed drug development approach to answer the question.

Org: Gilead Sciences, Inc., Foster City, CA, Certara, Inc., Princeton, NJ, Gilead Sciences Inc.,

Abstract

Role of HLA-DRB4 as a biomarker for endocrine toxicity and survival outcomes after immunotherapy in metastatic non-small cell lung cancer.

Org: University of Michigan, Fred Hutchinson Cancer Research Center, Beaumont Health, University of Michigan Health Management Research Center, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,

Abstract

Efficacy and safety of second-line treatment for advanced gastric cancer: A network meta-analysis of randomized controlled trials.

Org: National Cancer Center Hospital East, Kashiwa, Japan, National Clinical Research Center for Cancer, Cancer Hospital of Chinese Academy of Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Peking Union Medical College Hospital, Academy of Medical Sciences & Peking Union Medical College, Beijing, China,

Abstract

Mechanisms of sensitivity to platinum-based chemotherapy in PD-1 blockade-refractory head and neck cancer.

Org: Case Western Reserve School of Medicine, Cleveland, OH, Cleveland Clinic Taussig Cancer Instititute, OHB Neonatology,

Abstract

Final results: Dose escalation study of a personalized peptide-based neoantigen vaccine in patients with metastatic melanoma.

Org: National Center for Cancer Immune Therapy (CCIT-DK), Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Technical University of Denmark – DTU, HEALTH TECH, Department of Health Technology, Lyngby, Denmark, National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark, Center for Cancer Immune Therapy-CCIT Herlev Hospital (Denmark), Herlev, Denmark, Evaxion Biotech, Hoersholm, Denmark,

Abstract

Efficacy and safety of pembrolizumab plus chemotherapy and sequential surgical resection in initial unresectable stage IIIB NSCLC.

Org: Department of Respiratory Diseases, Thoracic Disease Center, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, Hefei, China, College of Medicine, University of the Philippines - Manila, Zhejiang University, Hangzhou, China,

Abstract

Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis.

Org: Federal University of Minas Gerais - UFMG, Princess Margaret Hospital, Federal University of Amazonas - UFAM, Federal University of Pará - UFPA, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto,

Abstract

Real-world experience and outcomes of immune-checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC).

Org: Ohio State University Comprehensive Canvcer Hospital, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, The Ohio State University Wexner Medical Center, Ohio State University Wexner Medical Center,

Abstract

Comparing PD-L1 scores for predicting pembrolizumab efficacy in first-line treatment of unresectable cutaneous squamous cell carcinomas.

Org: APHP Hôpital Avicenne, APHP Hôpital Bichat, Hopital Saint-André, Association de Cabinet de Radiologie et d'Imagerie Médicale, Polyclinique Saint-Côme, APHP Hôpital Saint-Louis,

Abstract

Dissecting the relationship between ethnicity and response to checkpoint inhibitors in patients with acral melanoma.

Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,

Abstract

KEYVIBE-010: Adjuvant coformulated vibostolimab with pembrolizumab versus adjuvant pembrolizumab in patients with high-risk stage II-IV melanoma.

Org: Faculty of Medicine University Medical Center and Princess Máxima Center, Utrecht, the Netherlands, Comprehensive Cancer Center Munich and Technical University Munich & Ludwig Maximilian University, Munich, Netherlands, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, University Hospital Essen, University Duisburg-Essen, West German Cancer Centre (WTZ), and German Cancer Consortium, Partner Site Essen, Essen, Germany, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy,

Abstract

The evolution of treatment patterns in patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) and clinical outcomes: Results of a longitudinal observational cohort study in England.

Org: Merck, Health Data Insight CIC, NHS Digital,

Abstract

Pembrolizumab immunotherapy in advanced and recurrent/metastatic salivary gland carcinoma (R/M SGC): A systematic review and meta-analysis.

Org: Federal University of Pelotas, Pelotas, Brazil, Brazil, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil,

Abstract

Five-year survival outcomes in patients with melanoma with complete response to immunotherapy who discontinue therapy.

Org: University of Pennsylvania Health System, Perelman Center for Advanced Medicine, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Abramson Cancer Center, University of Pennsylvania,

Abstract

Characterizing immune-genomic signatures associated with response to immune checkpoint inhibitors (ICI) in patients with metastatic urothelial carcinoma (mUC).

Org: Cleveland Clinic Lerner College of Medicine, John D. Dingell VA Hospital, Cleveland Clinic Taussig Cancer Instititute, Cleveland Clinic Lerner Research Institute, Cleveland, OH,

Abstract

Real-world efficacy and safety data of anti-PD-1 plus anti-CTLA-4 combination therapy in Chinese patients with advanced melanoma.

Org: Melanoma and Sarcoma Medical Oncology Unit, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center Gansu Hospital, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Biotherapy Center,

Abstract

Improving the care of patients with lung cancer hospitalized with immune checkpoint inhibitor-related pneumonitis: Implementation of a clinical pathway algorithm.

Org: University of Texas MD Anderson Cancer Center, MD Anderson Cancer Center,

Abstract

Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.

Org: University of Iowa Hospitals & Clinics, Iowa City VA Medical Center, Pfizer, New York Oncology Hematology PC, Nykode Therapeutics,

Abstract

Evolution of cancer treatment costs in the last 36 months in a self-funded health care in Brazil.

Org: CAPESESP,

Abstract

Association between immunotherapy and hypothyroidism in a Latin American population: An analytical study of cases and controls from 2019 to 2023.

Org: Hospital Fundación Santa Fe de Bogotá, Hospital Universitario Fundación Santa Fe de Bogotá,

Abstract

Impact of BAP1 mutational status on immunotherapy outcomes in advanced malignant pleural mesothelioma: A single institution experience.

Abstract

Eosinophil count and immune-related adverse events (irAEs) as predictive biomarkers of survival in patients with NSCLC treated with ICIs.

Org: Medical Oncology Unit, Ramazzini Hospital, Carpi, Italy, Careggi University Hospital, Department of Experimental and Clinical Medicine - Careggi University Hospital, Largo Brambilla, University of Florence, AOUC,

Abstract

Development of a kidney cancer ex vivo tumor model and image-based artificial intelligence tool for precision immunotherapy and combination therapy testing.

Org: Ourotech Ltd t/a Pear Bio, Royal Free London NHS Foundation Trust,

Abstract

Prediction of nonresponse and theranostic imaging in MIBC being resistant to NACT within the Bladder BRIDGister.

Org: STRATIFYER Molecular Pathology GmbH, ICPO Foundation,

Abstract

Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).

Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,

Abstract

Real-world evidence of first-line pembrolizumab plus chemotherapy in metastatic non-squamous NSCLC: A single-centre experience.

Org: Worcestershire Acute Hospitals NHS Trust, Worcester HIV Vaccine, Wet Midlands,

Abstract

Immune checkpoint inhibitors in cutaneous squamous cell carcinoma: A systematic review of clinical trials.

Org: BronxCare Health System, New York Medical College - Saint Michael's Medical Center, Saint Mary's and Saint Clare's Hospital, Mercy Hospital Fort Smith, Arkansas College of Osteopathic Medicine,

Abstract

Impact of PD-L1 and KRAS status on the efficacy of nintedanib (NIN) + docetaxel (DOC) following treatment with first-line immune checkpoint inhibitor (ICI) + chemotherapy in patients with adenocarcinoma NSCLC: Analysis of cohort C of the non-interventional VARGADO trial.

Org: Department of Respiratory Diseases, ELK Berlin, Universitätsklinikum Gießen und Marburg, Medizinische Klinik IV, Organonkologie, Innere Medizin V, Medizinische Klinik, Universitätskliniken des Saarlandes, Department of Internal Medicine, Klinikum Chemnitz GmbH,

Abstract

Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.

Org: Hôpital Européen Georges-Pompidou, Paris, Department of Medicine III and Comprehensive Cancer Center, University Hospital, LMU Munich, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, University Hospital 12 de Octubre, LMU Munich,

Abstract

“Interchangeability” of anti-PD1 antibodies in patients (pts) with metastatic melanoma (mM).

Org: Moskovskii Mnogoprofilnyi Klinicheskii Tcentr "Kommunarka" Departamenta Zdravoohraneniia Goroda Moskvy, N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of the Russian Federation, N.N. Blokhin NMRCO, N.N. Petrov Institute of Oncology, Kommunarka Moscow City Clinical Center,

Abstract

Patients characteristics, treatment patterns and clinical outcomes in patients with head and neck squamous cell carcinoma (aHNSCC) receiving immunotherapy in advanced setting: Retrospective cohort analysis of real-world data in Spain.

Org: Servicio de Oncología Médica, Hospital Universitario de Jaén, Jaén, Spain, Servicio de Farmacia Hospitalaria,

Abstract

Prognostic impact of baseline circulating extracellular vesicles (BCEVs) in the setting of patients with advanced non-small cell lung cancer (ANSCLC) eligible for first line treatment with osimertinib.

Org: Department of Surgical Oncological and Oral Sciences, University of Palermo, Dept of Surgery-Oncology and Oral Sciences, Institute of Translational Pharmacology (IFT), National Research Council (CNR) of Italy,

Abstract

Impact of SPARC expression on pembrolizumab treatment response and prognostic role in advanced stage non-small cell lung cancer.

Org: Istanbul Medipol University Medical Faculty, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,

Abstract

Immune checkpoint inhibitors in advanced cutaneous squamous cell carcinoma: Real-world evidence.

Org: Princess Margaret Cancer Centre, University Health Network, University of Toronto, Department of Medicine, Icahn School of Medicine at Mount Sinai, Division of Dermatology,

Abstract

Comparison of atezolizumab monotherapy to docetaxel with and without ramucirumab in patients with advanced non-small-cell lung cancer who received prior immunotherapy.

Org: Mayo Clinic Florida, Mayo Clinic,

Abstract

Treatment with lenvatinib plus pembrolizumab in recurrent or advanced endometrial cancer: A systematic review and meta-analysis.

Org: Federal University of Pará - UFPA, Belem, Brazil, Princess Margaret Hospital, Toronto Allergy and Asthma Centre,

Abstract

Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer.

Org: University Hospitals Cleveland Medical Center, Cleveland, OH, Case Western Reserve University School of Medicine, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center,

Abstract

A retrospective study evaluating the efficacy of pembrolizumab for metastatic or locally recurrent head and neck cancer: A real-world experience.

Org: Dartmouth-Hitchcock Medical Center, Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Dartmouth Hitchcock Medical Center, Geisel School of Medicine at Dartmouth,

Abstract

LAG3 landscape in solid tumors and its association with immunotherapy outcomes in non-small cell lung cancer.

Org: OmniSeq (Labcorp), OmniSeq Inc. (Labcorp), Labcorp Oncology, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Durham, NC,

Abstract

The utilization of lenvatinib with pembrolizumab for the treatment of recurrent endometrial cancer.

Org: Northwell Health Cancer Institute, Northwell Health, New Hyde Park, NY,

Abstract

Atezolizumab + intravesical BCG (bacillus Calmette-Guerin) upfront combination in high risk non–muscle- invasive bladder cancer (NMIBC) patients: Safety interim report of BladderGATE phase I-II study.

Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital Universitario 12 de Octubre, Unidad de Oncología Molecular CIEMAT, Unidad de Oncologia Molecular CIEMAT, Urology Department,

Abstract

Effect of immunotherapy cessation without disease progression on outcomes in patients with metastatic non-small cell lung cancer.

Org: Mayo Clinic Florida, Jacksonville, Mayo Clinic,

Abstract

Efficacy of immunotherapy in MSI metastatic colorectal cancer patients: A Real-World Italian multicentric retrospective study (Colon-MSI Study).

Org: Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana and Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy, Charité Universitätsmedizin Berlin, Berlin, Germany, Oncology Unit 1, Veneto Institute of Oncology IOV – IRCCS, Padua, Italy, Department of Medical Oncology, University Campus Biomedico, Roma, Italy, Division of Clinical Pharmacology and Oncology, Department of Health Sciences, School of Psychology, University of Florence, Florence, Italy, University of Pisa, Pisa, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS Padua, Padua, Italy, U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Livorno, Italy, Hämatologisch Onkologische Praxis Eppendorf (HOPE) and Universitäres Cancer Center Hamburg, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy, Department of Oncology, Istituto Scientifico San Raffaele IRCSS, Milan, Italy, CdC Poliambulanza, Brescia, Italy, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy and Oncology Unit 1 Veneto Institute of Oncology - IRCCS, Padua, Italy, IRCSS-CRO Aviano, Department of Clinical Oncology, Aviano, Italy, Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Martin Luther University, Halle, Germany, Azienda Ospedaliero-Universitaria Pisana, Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy,

Abstract

Association of tertiary lymphoid structures with outcomes from PD-1 inhibition in advanced malignant pleural mesothelioma.

Org: Centre Hospitalier Universitaire Vaudois, Frontier Science Foundation - Hellas, Immune Landscape Laboratory, Centre Thérapies expérimentales, Department of Oncology, CHUV - Centre Hospitalier Universitaire Vaudois,

Abstract

Patterns of failure in metastatic non-small cell lung cancer (mNSCLC) treated with first line pembrolizumab and use of local therapy in patients with oligoprogression.

Org: Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, PA, University of Pennsylvania, Philadelphia, PA, Division of of Pulmonary Medicine, Abraham Cancer Center, University of Pennsylvania, Philadelphia, PA, Department of Hematology/Oncology, University of Pennsylvania, Philadelphia, PA,

Product

Pembrolizumab + Dabrafenib + Trametinib

Abstract

Microsatellite instability in sarcomas: Which tests are ideal for diagnosis, and a systematic review.

Org: Hospital Israelita Albert Einstein,

Abstract

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.

Org: Arnie Charbonneau Cancer Research Institute, University of Calgary, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Alberta, Tom Baker Cancer Centre,

Abstract

Real world prognostic utility of body mass index and platelet lymphocyte ratio in first-line immunotherapy response in stage IV non-small cell lung cancer.

Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, California University of Science and Medicine, Division of Oncology, USC Keck School of Medicine,

Abstract

CAROLINE study: Incidence and characterization of melanoma in French Polynesia.

Org: Gustave Roussy Institute, Hopital Europeean Georges Pompidou, Universite Paris Cite, CHU Poitiers - Jean Bernard Hôpital, Centre Hospitalier de Polynésie Francaise - Site du Taaone-Pirae,

Abstract

First-line pembrolizumab plus platinum-pemetrexed in metastatic non-small cell lung cancer: Clinical experience in a Spanish tertiary hospital.

Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Hospital Universitario de Cruces, Hospital Universitario Donostia-Biodonostia, Hospital Universitario Cruces, Cruces University Hospital,

Abstract

Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in patients with non-small cell lung cancer receiving first-line treatment.

Org: McMaster University and Juravinski Cancer Centre, BioSpark AI Technologies, University of Massachusetts Chan Medical School,

Abstract

Immunotherapy and radiotherapy in metastatic uveal melanoma: Results from a single institute study.

Org: Houston Methodist Cancer Center, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Retina Consultants of Texas,

Clinical trial

An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

Status: Not yet recruiting, Estimated PCD: 2028-02-28

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20245

Abstract

https://www.abstractsonline.com/pp8/#!/10828/presentation/10249

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20189

Abstract

https://www.abstractsonline.com/pp8/#!/10517/presentation/20334

Abstract